ertapenem profile

Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	150610
CHEMBL ID	1359
CHEBI ID	404903
SCHEMBL ID	34454
MeSH ID	M0414190

Synonym
AC-6814
mk-826
mk-0826
l-749345
invanz (tn)
ertapenem
(1r,5s,6s,8r,2's,4's)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
(4r,5s,6s)-3-((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DB00303
ertapenem [inn]
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s,5s),4alpha,5beta,6beta(r*)))-
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl-4-methyl-7-oxo-, (4r,5s,6s)-
(4r,5s,6s)-3-[(3s,5s)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
153832-46-3
D07908
ertapenem (inn)
CHEMBL1359
chebi:404903 ,
(4r,5s,6s)-3-({(3s,5s)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4r,5r,6s)-3-((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-yl)sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
ertapenem [inn:ban]
unii-g32f6eid2h
hsdb 8020
g32f6eid2h ,
ertapenem [mi]
ertapenem [who-dd]
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s,5s), 4.alpha.,5.beta.,6.beta.(r*)))-
ertapenem [vandf]
(4r,5s,6s)-3-(((3s,5s)-5-((m-carboxyphenyl)carbamoyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
AKOS015895077
JUZNIMUFDBIJCM-ANEDZVCMSA-N
SCHEMBL34454
DTXSID50165456 ,
(4r,5s,6s)-3-{[(3s,5s)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
EX-A5317
ertapenem hydrochloride
Q553220
NCGC00387409-02
gtpl10906
C90412
mk0826
EN300-22104207
AS-83484
HY-A0294
CS-0020179
(4r,5s,6s)-3-((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo(3.2.0)hept-2-ene-2-carboxylic acid
j01dh03
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s,5s), 4alpha,5beta,6beta(r*)))-
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((3- carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1- hydroxyethyl-4-methyl-7-oxo-, (4r,5s,6s)-
dtxcid0087947
(4r,5s,6s)-3-(((3s,5s)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-yl)sulfanyl)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
ertapenemum

Excerpt	Reference	Relevance
"Ertapenem is a carbapenem antibiotic usually reserved for complicated infections. "	( Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis. Fernández-Rubio, B; Gil-Navarro, MV; Luque-Márquez, R, 2022)	2.58
"Ertapenem is a potential effective alternative for anogenital N gonorrhoeae infections and merits evaluation for ceftriaxone-resistant infections."	( Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Boyd, A; de Korne-Elenbaas, J; de Laat, M; de Vries, HJC; Heijman, T; Jongen, VW; Schim van der Loeff, MF; van Dam, AP; Wind, CM, 2022)	1.82
"Ertapenem has proven to be an effective antimicrobial; however, increasing enzyme-mediated resistance has been noted. "	( In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Abdelraouf, K; Chen, I; Gethers, M; Nicolau, DP, 2022)	2.45
"Ertapenem is a therapeutic option in patients with Gram-negative bone and joint infection (BJI). "	( Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. Chidiac, C; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Valour, F, 2018)	2.16
"Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections and is part of a broader class of antibiotics called carbapenems. "	( Modeling Ertapenem: the impact of body mass index on distribution of the antibiotic in the body. Bobola, V; Forbes, W; Frazier, W; Joyner, ML; Manning, CC, 2019)	2.37
"Ertapenem is a parenteral broad-spectrum carbapenem active against Gram-negative pathogens, which has been approved for treatment of different infectious situations in adults and children. "	( Population pharmacokinetics of ertapenem in juvenile and old rats. Boulamery, A; Bruguerolle, B; Marsot, A; Simon, N, 2014)	2.13
"Ertapenem is a broad-spectrum bactericidal carbapenem antibiotic. "	( [Pharmacological characteristics of ertapenem]. Suchánková, H; Urbánek, K, 2013)	2.11
"Ertapenem is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections. "	( Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Fisher, DA; Hee, KH; Lee, LS; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Zhou, J, 2014)	2.17
"Ertapenem appears to be a cost-saving strategy over piperacillin/tazobactam for the treatment of patients with complicated IAIs acquired in the community in Spain."	( Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis. Cavanillas, R; Grau, S; Lozano, V; Nocea, G; Valladares, A; Xie, Y, 2015)	2.09
"Ertapenem is a broad-spectrum and long-acting carbapenem which is predominantly eliminated by the kidneys, and it requires dose adjustment in renal failure. "	( Ertapenem-induced acute reversible peripheral neuropathy in chronic kidney disease: 3 case reports. Ayaz, T; Kara, E; Sahin, OZ; Sahutoglu, T; Tufekci, A; Yildirim, S, 2015)	3.3
"Ertapenem is an attractive carbapenem for the treatment of MDR- and XDR-TB because its relatively long half-life enables once-daily dosing.A retrospective study was performed for all patients with suspected MDR-TB at the Tuberculosis Center Beatrixoord of the University Medical Center Groningen (Haren, the Netherlands) who received ertapenem as part of their treatment regimen between December 1, 2010 and March 1, 2013."	( Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Akkerman, OW; Alffenaar, JW; de Lange, WC; Kosterink, JG; van Altena, R; van der Laan, T; van der Werf, TS; van Rijn, SP; van Soolingen, D, 2016)	1.48
"Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections, which is part of a broader class of antibiotics called carbapenem. "	( A physiologically-based pharmacokinetic model for the antibiotic ertapenem. Forbes, W; Joyner, ML; Maiden, M; Manning, CC; Nikas, AN, 2016)	2.11
"Ertapenem sodium is a β-lactam antibiotic of the carbapenem class that has a broader activity spectrum than most other β-lactam antimicrobials and is more resistant to the enzyme β-lactamase, which is the main mechanism of resistance of many bacteria."	( A Critical Review of Analytical Methods for Determination of Ertapenem Sodium. Pedroso, TM; Salgado, HR, 2016)	1.4
"Ertapenem is a broad-spectrum antibiotic that is increasingly being utilized. "	( Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. Archuleta, S; Chan, M; Fisher, DA; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Tan, SY; Trad, MA; Zhong, LH, 2017)	3.34
"Ertapenem sodium is a polar and ionizable compound; therefore, it has little retention on traditional C18 columns in reverse-phase high-performance liquid chromatography, even using a highly-aqueous mobile phase that can result in dewetting in the stationary phase. "	( RP-HPLC×HILIC chromatography for quantifying ertapenem sodium with a look at green chemistry. Medeiros, ACD; Pedroso, TM; Salgado, HRN, 2016)	2.14
"Ertapenem is an important first-line carbapenem antibiotic used for the treatment of aerobic Gram-negative bacterial infections. "	( The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug-Plasma Protein Binding Interactions. Baker, MA; Cooper, MA; Li, J; Schneider, EK; Velkov, T; X Huang, J, 2016)	2.15
"Ertapenem is a once-daily, broad-spectrum carbapenem antibiotic indicated for the treatment of complicated skin and skin-structure infections (cSSSI)."	( The use of ertapenem for the treatment of lower extremity infections. Catanzariti, AR; Mendicino, RW; Nielsen, MD, )	1.24
"Ertapenem appears to be a cost-saving and possibly an economically dominant therapy over piperacillin/tazobactam for the treatment of patients with DFIs from the UK NHS perspective."	( Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Carmeli, Y; Jansen, JP; Kumar, R, 2009)	2.02
"Ertapenem is a unique member of this class, with a narrower spectrum that lacks reliable activity against Pseudomonas and Enterococcus."	( Ertapenem. Congeni, BL, 2010)	2.52
"Ertapenem is a parenteral carbapenem licensed for use in adults and children more than 3 months of age. "	( Ertapenem. Bhattacharya, M; Krishnamurthy, S; Parakh, A, )	3.02
"Ertapenem is a carbapenem antibiotic with broad spectrum activity and a pharmacokinetic profile that favors once-daily administration in adults."	( Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Abdel-Rahman, SM; Blumer, JL; Groff, M; Herman, G; Jacobs, RF; Kearns, GL; Kitchen, CJ; Majumdar, A; Mistry, GC; Topelberg, S; Wagner, JA; Xu, Y, 2010)	2.04
"Ertapenem appears to be a safe and effective prophylaxis in patients with obstructive jaundice undergoing ERCP despite a limited biliary penetration in patients with high-grade obstruction."	( Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. Abdul-Baki, H; Aoun, E; Chaar, HF; El Hajj, II; Hashash, JG; Kanj, SS; Kyriacos, SB; Mansour, NM; Mroueh, M; Sharara, AI, 2011)	2.15
"Ertapenem is a broad spectrum carbapenem approved for the treatment of postpartum endometritis. "	( Ertapenem compared to combination drug therapy for the treatment of postpartum endometritis after cesarean delivery. Apuzzio, JJ; Brown, KR; Williams, SF, 2012)	3.26
"Ertapenem (Invanz) is a newly developed carbapenem β-lactam antimicrobial agent. "	( Development of an UPLC-MS/MS method for the determination of antibiotic ertapenem on dried blood spots. De Gaudio, M; De Martino, M; Filippi, L; Funghini, S; Galli, L; Giocaliere, E; la Marca, G; Malvagia, S; Ombrone, D; Villanelli, F, 2012)	2.05
"Ertapenem is a unique drug in that current dosing recommendations call for a 1 g dose for normal renal function patients, despite body weight."	( Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma. Brown, S; Pickering, M, 2013)	1.33
"Ertapenem (INVANZ) is a new once-a-day parenteral beta-lactam antimicrobial shown to be effective as a single agent for treatment of various community-acquired and mixed infections. "	( Pharmacokinetics of ertapenem in healthy young volunteers. Birk, KL; Blum, RA; Deutsch, P; Greenberg, H; Haesen, R; Hesney, M; Holland, S; Kitchen, CJ; Li, SX; Lins, RL; Majumdar, AK; McCrea, J; Mistry, G; Musson, DG; Rogers, JD; Waldman, S; Xi, L, 2002)	2.08
"Ertapenem is a new once-a-day antibiotic with excellent coverage of common community gram negative and gram positive aerobes and anaerobes. "	( Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma. Birk, KL; Fang, W; Hsieh, JY; Kitchen, CJ; Majumdar, AK; Musson, DG; Rogers, JD; Zhang, J, 2003)	2.01
"Ertapenem is a once-daily parenteral beta-lactam licensed in the United States in November 2001 and in Europe in May 2002."	( A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Cambronero-Hernandez, E; Carides, A; Isaacs, R; Oliveria, T; Rohlf, J; Simon, S; Vetter, N, 2002)	1.99
"Ertapenem (INVANZ) is a new once-a-day parental beta-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. "	( Pharmacokinetics of intramuscularly administered ertapenem. Birk, K; Deutsch, P; Fisher, A; Greenberg, H; Holland, S; Li, SX; Majumdar, A; Mistry, G; Musson, DG; Rogers, JD; Waldman, S; Wickersham, P, 2003)	2.02
"Ertapenem is a carbapenem that shares the activity of imipenem and meropenem against most species, but is less active against non-fermenters. "	( Properties and potential of ertapenem. Livermore, DM; Scott, GM; Sefton, AM, 2003)	2.06
"Ertapenem is a broad-spectrum parenteral antibiotic with activity against many Gram-negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria and is suitable for once-daily administration. "	( Ertapenem: a review of its use in the management of bacterial infections. Curran, M; Perry, C; Simpson, D, 2003)	3.2
"Ertapenem is a novel parenteral carbapenem with a long serum half-life. "	( In vitro activity of ertapenem against anaerobes isolated from the respiratory tract. Lauwers, S; Piérard, D; Roebben, E; Rosseel, P; Vandoorslaer, K; Wybo, I, 2003)	2.08
"Ertapenem is a new once-a-day parenteral carbapenem antimicrobial agent. "	( Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Birk, K; Deutsch, P; Holland, S; Majumdar, A; Mistry, G; Muckow, J; Musson, DG; Rogers, JD; Sciberras, D; Xi, L, 2004)	2.04
"Ertapenem is a broad-spectrum 1beta-methyl carbapenem with a long plasma half-life that allows administration of a single daily dose."	( In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. Alhambra, A; Alós, JI; Cacho, J; Cuadros, JA; Gómez-Garcés, JL, 2004)	1.27
"Ertapenem is a long-acting, 1beta-methyl parenteral Group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-a-day dosing supported by clinical studies. "	( In vitro activity of ertapenem: review of recent studies. Wexler, HM, 2004)	2.09
"Ertapenem is a once-a-day parenteral Group 1 carbapenem antibiotic, recently licensed in the USA and Europe, which may assume an important role in treating some complicated skin and skin-structure infections."	( Complicated infections of skin and skin structures: when the infection is more than skin deep. DiNubile, MJ; Lipsky, BA, 2004)	1.04
"Ertapenem is a Group 1 carbapenem that was licensed in the USA in November 2001 and in Europe in April 2002. "	( Safety and tolerability of ertapenem. Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL, 2004)	2.06
"Ertapenem is a parenteral carbapenem antimicrobial with pharmacological properties that allow it to be given once daily. "	( Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. Tice, AD, 2004)	3.21
"Ertapenem is a new carbapenem with a long half-life that has a broad spectrum of action against Gram-positive and Gram-negative bacteria. "	( [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates]. Alhambra, A; Alós, JI; Gómez-Garcés, JL; Hernáiz, C, 2005)	2.14
"Ertapenem is a powerful agent against the most common respiratory bacterial pathogens, including those with resistance mechanisms effective against other compouunds. "	( [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates]. Alhambra, A; Alós, JI; Gómez-Garcés, JL; Hernáiz, C, 2005)	2.14
"Ertapenem is a new carbapenem developed to address the pharmacokinetic shortcomings (short half-life) of imipenem and meropenem."	( Ertapenem: review of a new carbapenem. Embil, JM; Gin, A; Hoban, DJ; Johanson, C; Noreddin, A; Vercaigne, L; Zhanel, GG, 2005)	2.49
"Ertapenem (Invanz) is a newly developed carbapenem beta-lactam antibiotic. "	( Quantification of the carbapenem antibiotic ertapenem in human plasma by a validated liquid chromatography-mass spectrometry method. Deters, M; Kaever, V; Koal, T; Resch, K, 2006)	2.04
"Ertapenem is a new carbapenem with a broad spectrum of activity and an extended half-life, permitting once daily administration. "	( Assay of ertapenem in human serum by high-performance liquid chromatography. Lovering, AM; MacGowan, AP; Soltani, M, 2006)	2.19
"Ertapenem is an important newer broad-spectrum carbapenem antibiotic covering various infections caused by common gram-positive and -negative aerobes and anaerobes. "	( A new simple HPLC assay for the quantification of ertapenem in human plasma, lung tissue, and broncho-alveolar lavage fluid. Burkhardt, O; Drewelow, B; Majcher-Peszynska, J; Mundkowski, RG; Welte, T, 2006)	2.03
"Ertapenem is a carbapenem that shares the activity of imipenem and meropenem against most species, but is less active against non-fermenters. "	( [Ertapenem and other antibacterials]. , 2006)	2.69
"Ertapenem is a parenteral beta-lactam carbapenem antibiotic. "	( Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. Deutsch, PJ; Fisher, A; Hesney, M; Majumdar, AK; Mistry, GC; Sica, D; Swan, S; Wagner, JA; Xi, L; Xu, Y, 2006)	2.1
"Ertapenem is a long-acting 1-beta-methyl parenteral group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-daily dosing supported by clinical studies."	( Bactericidal activity of ertapenem against major intra-abdominal pathogens. Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S, 2006)	1.36
"Ertapenem is a novel carbapenem with activity against both penicillin-susceptible (MIC < or = 0.06 mg/L) and penicillin-non-susceptible (MIC > or = 0.12 mg/L) Streptococcus pneumoniae. "	( Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. Derkatch, S; Hoban, DJ; Laing, N; Noreddin, AM; Zhanel, GG, 2007)	2.08
"Ertapenem is a newer carbapenem with good in vitro activity against extended-spectrum beta-lactamase (ESBL)-producing organisms."	( Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. Bassetti, M; Di Biagio, A; Fasce, R; Molinari, MP; Mussap, M; Pallavicini, FB; Righi, E; Rosso, R; Viscoli, C, 2007)	1.44
"Ertapenem is a once-a-day carbapenem and has excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria. "	( Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. Fung, CP; Huang, SS; Lee, CW; Lee, N; Lee, SC; Shieh, WB; Siu, LK, 2007)	1.99
"Ertapenem is a new carbapenem, exhibiting activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria commonly recovered from community-acquired infections."	( Diffusion of ertapenem into bone and synovial tissues. Allaouchiche, B; Bel, JC; Boselli, E; Breilh, D; Djabarouti, S; Saux, MC, 2007)	1.43
"Ertapenem is a promising new treatment for patients with pneumococcal pneumonia, including those at risk of infection with a fluoroquinolone-resistant strain."	( Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia. Bast, DJ; De Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Walker, SE, 2007)	1.35
"Ertapenem is a new member of the carbapenem class of antibiotics, with a favourable pharmacokinetic profile, but a narrower spectrum of antimicrobial activity, compared with older representatives of this class."	( Meta-analysis: ertapenem for complicated intra-abdominal infections. Falagas, ME; Karageorgopoulos, DE; Makris, GC; Matthaiou, DK; Peppas, G, 2008)	2.14
"Ertapenem is a new carbapenem with an excellent activity against different Gram-negative and Gram-positive bacteria. "	( [In vitro activity of ertapenem against staphylococci]. Goldu, I; Poiata, A; Tuchiluş, C, )	1.89
"Ertapenem is a new 1-beta-methyl carbapenem, stable to dehydropeptidase, which binds preferable to penicillin-binding proteins (PBP) 2 and 3. "	( Ertapenem: a new carbapenem. Odenholt, I, 2001)	3.2
"Ertapenem is a new, structurally unique, parenteral beta-lactam antimicrobial agent that can be administered once daily."	( Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Friedland, I; Jiang, Q; Legua, P; Lema, J; Moll, J; Woods, G, 2002)	2

Excerpt	Reference	Relevance
"Ertapenem/zidebactam has a proposed once-daily regimen well suited to OPAT. "	( Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales. Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N, 2022)	2.54
"Ertapenem has a pharmacokinetic profile and antimicrobial spectrum that support the potential for use as a once-a-day agent for the treatment of common mixed aerobic and anaerobic infections. "	( Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Carides, A; Choe, KA; Christou, NV; Dellinger, EP; Fernandez, A; Malafaia, O; Rotstein, OD; Satishchandran, V; Solomkin, JS; Tellado, JM; Teppler, H; Yellin, AE, 2003)	3.2
"Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved."	( Ertapenem: a review of its use in the management of bacterial infections. Curran, M; Perry, C; Simpson, D, 2003)	2.48
"Ertapenem has a broad spectrum of in vitro activity against Gram-negative pathogens, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, Gram-positive pathogens and anaerobic pathogens."	( Ertapenem: a review of its use in the treatment of bacterial infections. Keating, GM; Perry, CM, 2005)	2.49
"Ertapenem has an activity comparable to the other tested agents."	( [In vitro activity of ertapenem against staphylococci]. Goldu, I; Poiata, A; Tuchiluş, C, )	1.17
"Ertapenem has a broad antibacterial spectrum with MIC90 values < 0.5 mg/l for penicillin-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Serratia spp., Proteus spp., Clostridium perfringens, Fusobacterium spp."	( Ertapenem: a new carbapenem. Odenholt, I, 2001)	2.47
"Ertapenem (EPM) has been recently approved by the United States Food and Drug Administration (US-FDA) as an antimicrobial drug. "	( Bio-analytically fluorimetric method for estimation of ertapenem in real human plasma and commercial samples; application to pharmacokinetics study. Salman, BI; Saraya, RE, 2022)	2.41
"Ertapenem has proven to be an effective antimicrobial; however, increasing enzyme-mediated resistance has been noted. "	( In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Abdelraouf, K; Chen, I; Gethers, M; Nicolau, DP, 2022)	2.45
"Ertapenem/zidebactam has a proposed once-daily regimen well suited to OPAT. "	( Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales. Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N, 2022)	2.54
"Ertapenem has been suggested as a not carbapenem-resistance inducer."	( Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review. Gasparetto, J; Telles, JP; Tuon, FF; Zequinão, T, 2020)	1.57
"Ertapenem has proven to be effective for extended-spectrum beta-lactamases-producing Enterobacteriaceae but lacks activity against non-fermenters; de-escalation to this antibiotic may reduce the selection of resistance to Pseudomonas aeruginosa and improve clinical outcomes."	( [Clinical impact of ertapenem de-escalation in critically-ill patients with Enterobacteriaceae infections]. Blanco, VM; Camargo, RD; Correa, A; Cuesta, DP; Florez, E; Hernández-Gómez, C; Matta, L; Maya, JJ; Motoa, G; Muñoz, M; Nagles, J; Ovalle, A; Reyes, S; Rosso, F; Vallejo, ME; Villegas, MV, 2019)	2.28
"Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. "	( Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials. Bai, N; Cai, Y; Liang, B; Liu, Y; Sun, C; Wang, J; Wang, R; Zhang, L, 2014)	3.29
"Ertapenem has unique characteristics that may make it useful in specific clinical circumstances that are detailed in this review."	( Ertapenem. Congeni, BL, 2010)	2.52
"Ertapenem exposure has been reported to select for cross-resistance to other carbapenems in Pseudomonas aeruginosa in vitro. "	( Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Eagye, KJ; Nicolau, DP, 2010)	2.07
"Ertapenem has been proven to be clinically and bacteriologically efficacious in randomised controlled trials for the treatment of community acquired infections including complicated intra-abdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections, community-acquired pneumonia and for the prophylaxis of surgical-site infection following elective colorectal surgery."	( Ertapenem. Bhattacharya, M; Krishnamurthy, S; Parakh, A, )	2.3
"Ertapenem has a pharmacokinetic profile and antimicrobial spectrum that support the potential for use as a once-a-day agent for the treatment of common mixed aerobic and anaerobic infections. "	( Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Carides, A; Choe, KA; Christou, NV; Dellinger, EP; Fernandez, A; Malafaia, O; Rotstein, OD; Satishchandran, V; Solomkin, JS; Tellado, JM; Teppler, H; Yellin, AE, 2003)	3.2
"Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved."	( Ertapenem: a review of its use in the management of bacterial infections. Curran, M; Perry, C; Simpson, D, 2003)	2.48
"Ertapenem has potent activity against the majority of anaerobic isolates from intra-abdominal infections, and against most of the aerobes isolated from these infections, with the exceptions of the nosocomial pathogens mentioned above."	( In vitro activity of ertapenem: review of recent studies. Wexler, HM, 2004)	1.36
"Ertapenem has a broad spectrum of in vitro activity against Gram-negative pathogens, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, Gram-positive pathogens and anaerobic pathogens."	( Ertapenem: a review of its use in the treatment of bacterial infections. Keating, GM; Perry, CM, 2005)	2.49
"Ertapenem has limited efficacy against non-fermenting, Gram-negative bacteria, restricting its use to community-acquired infections."	( Carbapenems: a potent class of antibiotics. Nicolau, DP, 2008)	1.07
"Ertapenem has an activity comparable to the other tested agents."	( [In vitro activity of ertapenem against staphylococci]. Goldu, I; Poiata, A; Tuchiluş, C, )	1.17
"Ertapenem has a broad antibacterial spectrum with MIC90 values < 0.5 mg/l for penicillin-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Serratia spp., Proteus spp., Clostridium perfringens, Fusobacterium spp."	( Ertapenem: a new carbapenem. Odenholt, I, 2001)	2.47

Excerpt	Reference	Relevance
"Ertapenem treatment resulted in a markedly lower rate of clinical resolution in severe DFIs."	( Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS, 2016)	2.6
"Ertapenem-treated patients received longer outpatient antibiotic treatment (10 days vs."	( Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Davis, SL; Grunwald, JL; Kenney, RM; Veve, MP; Wagner, JL, 2016)	1.45
"Each ertapenem-treated patient was matched with two patients in the same hospital treated with other antibiotics, according to age (difference	( Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Aguilar, L; Barberán, J; González-Comeche, J; González-Moreno, J; González-Pina, B; Granizo, JJ; Irurzun, J; López-Dupla, M; Marín, A; Murcia, JM, 2009)	1.13
"Treatment with ertapenem was non-inferior to piperacillin/tazobactam in Chinese patients with DFIs. "	( Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS, 2016)	2.23
"Treatment with ertapenem reduced the viability of E."	( In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. Apolônio, ACM; Coutinho, SC; Diniz, CG; Farias, LM; Geralda de Sousa-Gaia, L; Nicoli, JR; Roque de Carvalho, MA; Valéria Dos Santos, K, 2007)	0.93

Excerpt	Reference	Relevance
" Both treatment regimens were generally well tolerated; the most common drug-related adverse events reported were diarrhea (2."	( A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Caballero-Lopez, J; Carides, A; Friedland, IR; Ortiz-Ruiz, G; Woods, GL, 2002)	0.56
" Clinical drug-related adverse events were reported during IM therapy in 14 patients (16."	( Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Friedland, I; Jiang, Q; Legua, P; Lema, J; Moll, J; Woods, G, 2002)	0.56
" The frequencies of drug-related adverse events, most commonly diarrhea and elevated serum alanine aminotransferase levels, were similar in both treatment groups."	( Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. Asperger, W; Chan, CY; Dela Pena, AS; DiNubile, MJ; Giezek, H; Kafka, R; Köckerling, F; Raz, R; Shivaprakash, M; Vrijens, F; Warren, B, 2006)	0.64
" There were no statistical differences between the groups in serious drug-related clinical adverse events, drug-related clinical adverse experiences leading to study discontinuation, or mortality."	( Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Abramson, MA; Jensen, EH; Namias, N; Solomkin, JS; Tomassini, JE, 2007)	0.56
" The primary outcome was the incidence of clinical and laboratory drug-related serious adverse events (AEs)."	( Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Arguedas, A; Blumer, J; Botet, FA; Cespedes, J; Gesser, R; Snyder, T; Wang, J; West, J; Wimmer, W; Yogev, R, 2009)	0.65
"To report stroke-like symptoms and unusual central nervous system adverse effects in 2 elderly patients receiving ertapenem."	( Central nervous system toxicity associated with ertapenem use. Duquaine, S; Kitchell, E; Tannen, RC; Tate, T; Wickremasinghe, IM, 2011)	0.84
" When applied to our patients, the Naranjo probability scale indicated a highly probable relationship for patient 1 and a probable relationship for patient 2 between the adverse effects and ertapenem use."	( Central nervous system toxicity associated with ertapenem use. Duquaine, S; Kitchell, E; Tannen, RC; Tate, T; Wickremasinghe, IM, 2011)	0.82
" Patients were observed for 72 hours for cholangitis or drug-related adverse events."	( Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. Abdul-Baki, H; Aoun, E; Chaar, HF; El Hajj, II; Hashash, JG; Kanj, SS; Kyriacos, SB; Mansour, NM; Mroueh, M; Sharara, AI, 2011)	0.71
" No drug-related adverse events were noted."	( Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. Abdul-Baki, H; Aoun, E; Chaar, HF; El Hajj, II; Hashash, JG; Kanj, SS; Kyriacos, SB; Mansour, NM; Mroueh, M; Sharara, AI, 2011)	0.71
"Ertapenem appears to be a safe and effective prophylaxis in patients with obstructive jaundice undergoing ERCP despite a limited biliary penetration in patients with high-grade obstruction."	( Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration. Abdul-Baki, H; Aoun, E; Chaar, HF; El Hajj, II; Hashash, JG; Kanj, SS; Kyriacos, SB; Mansour, NM; Mroueh, M; Sharara, AI, 2011)	2.15
" The incidences of treatment-emergent adverse events were 35."	( Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Cesnauskas, G; Horn, PT; Novikovs, N; Ramesh, MK; Solomkin, JS; Stefanova, P; Sutcliffe, JA; Walpole, SM, 2014)	0.61
" Of the 6 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of therapy and 4 required additional source control for clinical success."	( Safety and efficacy of long-term outpatient ertapenem therapy. Doi, Y; Qureshi, ZA; Syed, A, 2014)	0.66
" Neurotoxicity, specifically seizures, due to ertapenem is a known adverse effect and has been described previously."	( Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: A case series. Fowler, MA; Patel, UC, 2018)	2.18
"9%, and of adverse drug reactions -3."	( Effectiveness and safety of ertapenem used in hospital-at-home units: data from Spanish Outpatient Parenteral Antimicrobial Therapy Registry. Abad, A; Aguilera, A; Escalada, C; Estrada, O; García, D; Gómez, MJ; González, CR; González, S; González-Ramallo, VJ; Mirón-Rubio, M; Mujal, A; Muñoz, P; Pajarón, M; Parra, JJ; Pereda, I; Sampedro, I; Sanroma, P; Sgaramella, GA; Solé, A; Vitoria, I, 2018)	0.77
" This study aims to evaluate whether a short course of antimicrobial therapy is safe and effective in cases with ASB before urological procedures."	( A short course of antimicrobial therapy for asymptomatic bacteriuria is safe and effective before urologic procedures. Arslan, M; Aybek, Z; Kutlu, M; Ozdemir, K; Ozlulerden, Y; Sayin-Kutlu, S, 2021)	0.62
" Neurotoxicity is a rare adverse effect, most often associated with imipenem (0."	( Ertapenem neurotoxicity in liver transplantation. Aguilera Sancho-Tello, MV; Conde, I; García Eliz, M; Ladrón Abia, P; Martínez Delgado, S; Mínguez Sabater, A, 2022)	2.16
" However, studies evaluating the ertapenem blood concentration (EBC) as a risk of these adverse events are scarce."	( Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity. Anguita-Domingo, D; Campany-Herrero, D; González-Moreno, P; Montoro-Ronsano, B; Pau-Parra, A; Vima-Bofarull, J, 2023)	2.63
" The main outcome was the presence of any suspicious neurological side effect owing to ertapenem administration and its relationship with the plasma concentration."	( Ertapenem blood concentration: A retrospective cohort study to analyse risk of neurotoxicity. Anguita-Domingo, D; Campany-Herrero, D; González-Moreno, P; Montoro-Ronsano, B; Pau-Parra, A; Vima-Bofarull, J, 2023)	2.58

Excerpt	Reference	Relevance
" Ertapenem was given subcutaneously at 50 mg/kg of body weight every 6 h, which simulates the human pharmacodynamic profile (in particular, the duration of time that the concentration of free drug remains above the MIC of 2 mg/liter)."	( Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Banevicius, M; Capitano, B; Kim, MK; Nicolau, D; Nightingale, C; Xuan, D, 2002)	1.51
" dose infused over 120 min, the geometric mean area under the concentration curve from hour 0 to infinity (AUC(0- infinity )) was 541."	( Pharmacokinetics of intramuscularly administered ertapenem. Birk, K; Deutsch, P; Fisher, A; Greenberg, H; Holland, S; Li, SX; Majumdar, A; Mistry, G; Musson, DG; Rogers, JD; Waldman, S; Wickersham, P, 2003)	0.57
" Concentrations in plasma and the half-life of ertapenem were generally higher and longer, respectively, in elderly subjects than in young adults."	( Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Birk, K; Deutsch, P; Holland, S; Majumdar, A; Mistry, G; Muckow, J; Musson, DG; Rogers, JD; Sciberras, D; Xi, L, 2004)	0.85
" For ertapenem the maximum concentration of the drug in plasma (C(max)) was 256 mg/liter, the half-life was 20."	( Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Bulitta, J; Burkhardt, O; De Roux, A; Kruse, G; Kurowski, M; Lode, H; Nord, CE; Pletz, MW; Rau, M, 2004)	2.28
"The pharmacodynamic profile of ertapenem was evaluated in a neutropenic mouse thigh infection model."	( Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Babalola, C; Banevicius, MA; Maglio, D; Nicolau, DP; Nightingale, CH; Sutherland, C, 2005)	0.91
" Monte Carlo simulation was used to construct pharmacodynamic models for imipenem, meropenem, ertapenem, levofloxacin, gatifloxacin, and ciprofloxacin."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.54
" In the pharmacodynamic models, imipenem and meropenem had an equal likelihood of achieving a free T>MIC > or =40% against bacteria that produced ESBLs (> or =97%) and bacteria that did not produce ESBLs (> or =98%)."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.32
" Pharmacodynamic modeling based on local ESBL-producing isolates and pharmacokinetic data from healthy humans indicated that imipenem and meropenem may have a greater likelihood of achieving pharmacodynamic targets against bacteria that produce ESBLs than ertapenem or fluoroquinolones."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.5
" Population pharmacokinetic data were obtained using a nonparametric adaptive grid followed by Monte Carlo simulation to determine the probability of obtaining the free drug exposure targets of the time that the free drug concentration remains above the MIC (fT>MIC) of 20% and 40% for bacteriostatic and maximal bactericidal activity, respectively."	( Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Bertino, JS; Chen, M; Drusano, GL; Ma, L; Nafziger, AN, 2006)	0.57
"The pharmacodynamic potency of imipenem, meropenem and ertapenem against extended-spectrum beta-lactamase (ESBL)-producing isolates was investigated."	( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)	0.83
" The in vitro pharmacodynamic model was inoculated with 1 x 10(6) cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate f (free) Cmax and t(1/2) obtained after a standard 1 g intravenous once daily dose in healthy volunteers (fCmax 15 mg/L, t(1/2) 4 h)."	( Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. Derkatch, S; Hoban, DJ; Laing, N; Noreddin, AM; Zhanel, GG, 2007)	0.86
" However, antibiotics are therapeutically used in infected patients with very different pharmacokinetic properties compared with healthy individuals."	( Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. Burkhardt, O; Derendorf, H; Drewelow, B; Katterwe, D; Kumar, V; Majcher-Peszynska, J; Welte, T, 2007)	1.78
" Pharmacokinetic parameters of ertapenem in our critically ill patients were clearly different when compared to those reported in the literature for healthy volunteers."	( Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. Burkhardt, O; Derendorf, H; Drewelow, B; Katterwe, D; Kumar, V; Majcher-Peszynska, J; Welte, T, 2007)	2.07
"This study assessed the pharmacodynamic activity of ertapenem against multidrug-resistant (MDR) genotypically characterized extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli using an in vitro model."	( Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model. Baudry, P; Hoban, DJ; Laing, N; Noreddin, AM; Vashisht, V; Zhanel, GG, 2008)	0.89
" The in vitro pharmacodynamic model was inoculated with 1 x 10(6) cfu/mL, and ertapenem was dosed once daily at 0 and 24 h to simulate free (f) Cmax and t(1/2) obtained after a standard 1 g intravenous once-daily dose in healthy volunteers (fCmax, 15 mg/L; t(1/2), 4 h)."	( Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model. Baudry, P; Hoban, DJ; Laing, N; Noreddin, AM; Vashisht, V; Zhanel, GG, 2008)	0.87
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The highly variable and unpredictable intersubject pharmacokinetic parameters documented in this study resulted in suboptimal unbound concentrations in some patients."	( Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Brink, AJ; Kiem, S; Richards, GA; Schentag, J; Schillack, V, 2009)	0.62
"Ertapenem is a carbapenem antibiotic with broad spectrum activity and a pharmacokinetic profile that favors once-daily administration in adults."	( Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Abdel-Rahman, SM; Blumer, JL; Groff, M; Herman, G; Jacobs, RF; Kearns, GL; Kitchen, CJ; Majumdar, A; Mistry, GC; Topelberg, S; Wagner, JA; Xu, Y, 2010)	2.04
"The aim of this paper was to compare the pharmacokinetic and pharmacodynamic (PK/PD) parameters of continuous (CI) and intermittent infusion (ITI) of ertapenem into critically ill patients with severe abdominal infections."	( Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion. Boselli, E; Breilh, D; Fleureau, C; Gordien, JB; Janvier, G; Joanes-Boyau, O; Rapaport, S; Saux, MC; Texier-Maugein, J, 2011)	0.87
" q24h was very likely (>90%) to achieve the pharmacodynamic target for MICs of ≤2 mg/liter."	( Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Cardone, KE; Daoui, R; Drusano, GL; Grabe, DW; Kulawy, RW; Lodise, TP; Meola, S; Roglieri, J, 2012)	1.82
" Free interstitial Cmax in the infected leg (4."	( Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. Burian, A; Burian, B; Höferl, M; Jäger, W; Riedl, M; Sauermann, R; Stella, A; Theurer, S; Zeitlinger, M, 2013)	0.69
"Prospective, randomized, crossover pharmacokinetic study."	( Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Housman, ST; Kuti, JL; Nicolau, DP; Quintiliani, R; Wiskirchen, DE, 2013)	0.63
" Pharmacokinetic analyses were conducted using noncompartmental and compartmental methods."	( Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Housman, ST; Kuti, JL; Nicolau, DP; Quintiliani, R; Wiskirchen, DE, 2013)	0.63
"The aims of this study were to evaluate pharmacokinetic (PK) parameters of total and unbound ertapenem (ERT) in burns patients and to identify which covariates influence these PK parameters."	( Pharmacokinetics of ertapenem in burns patients. Arnould, JF; Bouquié, R; Dailly, E; Deslandes, G; Fraissinet, F; Jolliet, P; Le Floch, R; Letard de la Bouralière, MA; Naux, E, 2013)	0.93
" Nevertheless, pharmacokinetic studies in paediatrics have not been published yet."	( Population pharmacokinetics of ertapenem in juvenile and old rats. Boulamery, A; Bruguerolle, B; Marsot, A; Simon, N, 2014)	0.69
" Ertapenem total serum, unbound serum, and effluent concentrations from all eight subjects were used simultaneously to perform a population compartmental pharmacokinetic modeling procedure using NONMEM."	( Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. DePestel, DD; Eyler, RF; Heung, M; Kinzig, M; Mueller, BA; Nader, AM; Pleva, M; Sörgel, F; Sowinski, KM; Vilay, AM, 2014)	1.64
"Since antimicrobial resistance among uropathogens against current first line agents has affected the management of severe urinary tract infection, we determined the likelihood that antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte Carlo simulation for five antimicrobials (ciprofloxacin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpatients with severe community acquired urinary tract infections."	( Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract. Cuba, GT; Kiffer, CR; Luchesi, LJ; Patekoski, KS; Pignatari, AC, )	0.3
" A population pharmacokinetic model was used to characterize ertapenem serum and urine profiles."	( Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Fisher, DA; Hee, KH; Lee, LS; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Zhou, J, 2014)	0.97
" The in vitro pharmacodynamic model was inoculated with ∼1 × 10(6) cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate free (ƒ) Cmax and t½ obtained after either 1 g or 2 g intravenous once-daily doses in healthy volunteers (1 g: ƒCmax 15 mg/L, t½ 4 h)."	( Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. Adam, HJ; Denisuik, A; Hoban, DJ; Vashisht, S; Yachison, C; Zhanel, GG, 2014)	0.92
" Ertapenem is an attractive carbapenem for the treatment of MDR- and XDR-TB because its relatively long half-life enables once-daily dosing."	( Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Akkerman, OW; Alffenaar, JW; de Lange, WC; Kosterink, JG; van Altena, R; van der Laan, T; van der Werf, TS; van Rijn, SP; van Soolingen, D, 2016)	1.67
" Unlike other carbapenems, ertapenem has a longer half-life and thus only has to be administered once a day."	( A physiologically-based pharmacokinetic model for the antibiotic ertapenem. Forbes, W; Joyner, ML; Maiden, M; Manning, CC; Nikas, AN, 2016)	0.97
" Then, simulations were performed based on the final model to investigate the influence of ertapenem route of administration, dosage and renal function on the probability of achieving a pharmacodynamic (PD) target, defined as the percentage of time for which free plasma concentrations of ertapenem remained above the MIC (fT>MIC) of 40%."	( Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. Chidiac, C; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Valour, F, 2018)	0.94
"Previous pharmacokinetic studies demonstrated an increase in serum ertapenem concentrations with decreasing kidney function, including patients receiving renal replacement therapy."	( Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Cha, R; Desai, NH; Hsaiky, LM; Jennings, ST; Lobkovich, AM; Salinitri, FD; Wong, J, 2019)	1
"Following an IV bolus of 1 g ertapenem, plasma concentrations declined relatively slowly with a mean ±standard deviation (SD) elimination half-life of 19."	( Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Cha, R; Desai, NH; Hsaiky, LM; Jennings, ST; Lobkovich, AM; Salinitri, FD; Wong, J, 2019)	1.06
"Ertapenem half-life was prolonged in hemodialysis patients."	( Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Cha, R; Desai, NH; Hsaiky, LM; Jennings, ST; Lobkovich, AM; Salinitri, FD; Wong, J, 2019)	2.21
"Ertapenem is used off-label to treat osteoarticular infections but there are few pharmacokinetic (PK) data to guide optimal dosing strategies in patients who may be obese with multiple co-morbidities including diabetes and peripheral vascular disease."	( Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. Batty, KT; Chambers, J; Davis, TME; Dyer, J; Manning, L; Page-Sharp, M; Salman, S, 2019)	3.4

Excerpt	Reference	Relevance
"Linezolid in combination with ertapenem showed in vitro synergy against methicillin-resistant Staphylococcus aureus strains."	( In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Batard, E; Bugnon, D; Caillon, J; Grossi, O; Jacqueline, C; Le Mabecque, V; Miegeville, AF; Potel, G, 2006)	0.87
" This study systematically evaluated by in vitro time-kill studies the effect of daptomycin in combination with ampicillin, cefazolin, ceftriaxone, ceftaroline, ertapenem, gentamicin, tigecycline, and rifampin, for a collection of 9 daptomycin-NS enterococci that exhibited a broad range of MICs and different resistance-conferring mutations."	( In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Carvalho, M; Charlton, CL; Hindler, JA; Humphries, R; Kelesidis, T; Miller, SA; Nizet, V; Nonejuie, P; Pogliano, J; Sakoulas, G; Wong-Beringer, A, 2015)	0.61
" The SBPI analysis showed that CAZ-AVI in combination with imipenem achieved higher SBPI values than other CAZ-AVI-based combinations."	( In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL, 2017)	0.46
" Zinc in combination with aminoglycosides (kanamycin, gentamicin, and amikacin) reduced the expression of biofilm-related genes by 40-, 2602- and 20-folds, respectively, and by 2-folds in combination with ertapenem."	( Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate. Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)	1.1
"Results revealed variable interaction patterns between different antibiotics in combination with zinc."	( Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate. Badawy, MSEM; Elkhatib, WF; Shebl, RI, 2023)	0.91

Excerpt	Reference	Relevance
" Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales, including extended-spectrum beta-lactamase-producing and fluoroquinolone-resistant strains."	( Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. Critchley, IA; Dane, A; Eckburg, PB; Jain, A; Keutzer, T; Kwak, H; Melnick, D; Moore, G; Muir, L; Phelan, AM; Talley, AK; Walpole, S, 2022)	0.72
"Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections."	( Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber Ambrose, PG; Bhavnani, SM; Conde, H; Cotroneo, N; Friedrich, LV; Jones, S; VanScoy, BD, 2023)	1.14

Excerpt	Relevance	Reference
", killing of approximately 2 log CFU per thigh) were consistently observed against isolates for which MICs were	( Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Banevicius, M; Capitano, B; Kim, MK; Nicolau, D; Nightingale, C; Xuan, D, 2002)	0.6
" Its high level of protein binding and serum half-life of 4 h allows it to be dosed once daily."	( Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Cunha, BA, 2002)	1.76
" Concentrations of ertapenem in blister fluid exceeded 4 micro g/ml (the MIC at which 90% of the isolates tested are eliminated) for the entire dosing interval."	( Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. De Lepeleire, I; Deutsch, P; Guillaume, M; Laethem, T; Li, S; Majumdar, A; McCrea, J; Musson, D; Parneix-Spake, A; Rogers, D; Zhang, J, 2003)	0.96
" As in young adults, ertapenem did not accumulate upon multiple dosing in the elderly."	( Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Birk, K; Deutsch, P; Holland, S; Majumdar, A; Mistry, G; Muckow, J; Musson, DG; Rogers, JD; Sciberras, D; Xi, L, 2004)	0.91
" While structurally a carbapenem, the overall molecular structure of ertapenem has been modified to focus its antibacterial spectrum on important community-acquired aerobic and anaerobic pathogens, and to increase its plasma half-life, permitting once-a-day dosing for this parenteral antibiotic."	( Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. Hammond, ML, 2004)	2
"Ertapenem is a long-acting, 1beta-methyl parenteral Group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-a-day dosing supported by clinical studies."	( In vitro activity of ertapenem: review of recent studies. Wexler, HM, 2004)	2.09
" Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections."	( Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. DiNubile, MJ; Majumdar, AK; Nix, DE, 2004)	0.92
" Ertapenem doses were administered once to five times daily to achieve various exposures, reported as the percentage of the dosing interval that the concentration of free ertapenem was in excess of the MIC (%T>MIC(free))."	( Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Babalola, C; Banevicius, MA; Maglio, D; Nicolau, DP; Nightingale, CH; Sutherland, C, 2005)	1.54
" Since, following a 1 g intravenous dose the free ertapenem concentration in the serum falls below 4 mg/L--corresponding to the lower of two MIC(50) estimates--within 4 h (17% of the dosage interval) selectivity in vivo should be minimized."	( Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. Livermore, DM; Mushtaq, S; Warner, M, 2005)	0.93
" Pharmacodynamic exposure, measured as percent of the dosing interval during which free drug was above the MIC (% fT>MIC), was modelled via a 5000-subject Monte Carlo simulation."	( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)	0.58
" Ertapenem is a long-acting 1-beta-methyl parenteral group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-daily dosing supported by clinical studies."	( Bactericidal activity of ertapenem against major intra-abdominal pathogens. Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S, 2006)	1.55
" The in vitro pharmacodynamic model was inoculated with 1 x 10(6) cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate f (free) Cmax and t(1/2) obtained after a standard 1 g intravenous once daily dose in healthy volunteers (fCmax 15 mg/L, t(1/2) 4 h)."	( Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. Derkatch, S; Hoban, DJ; Laing, N; Noreddin, AM; Zhanel, GG, 2007)	0.86
" A shortening of the dosage interval or continuous infusion of ertapenem should be considered to ensure optimal free concentrations in critically ill patients with severe hypoalbuminaemia and normal renal function."	( Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. Burkhardt, O; Derendorf, H; Drewelow, B; Katterwe, D; Kumar, V; Majcher-Peszynska, J; Welte, T, 2007)	2.02
" Therefore, a shortening of the dosage interval or continuous infusion of ertapenem should be considered to ensure optimal free concentrations in these particular populations."	( Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Burkhardt, O; Derendorf, H; Welte, T, 2007)	2.01
" His divalproex sodium dosage was increased, and he was released from the emergency department only to return 4 days later with recurring seizures."	( Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Lunde, JL; Nelson, RE; Storandt, HF, 2007)	0.57
" Ertapenem is the newest carbapenem, capable of being dosed once daily, and has some in vitro but little in vivo evidence supporting its use for the treatment of these resistant infections."	( Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Berg, ML; Crank, CW; Hayden, MK; Philbrick, AH, 2008)	1.64
" The in vitro pharmacodynamic model was inoculated with 1 x 10(6) cfu/mL, and ertapenem was dosed once daily at 0 and 24 h to simulate free (f) Cmax and t(1/2) obtained after a standard 1 g intravenous once-daily dose in healthy volunteers (fCmax, 15 mg/L; t(1/2), 4 h)."	( Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model. Baudry, P; Hoban, DJ; Laing, N; Noreddin, AM; Vashisht, V; Zhanel, GG, 2008)	0.87
"1h (30%) of the dosing interval in two patients."	( Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Brink, AJ; Kiem, S; Richards, GA; Schentag, J; Schillack, V, 2009)	0.62
" If in vivo studies corroborate our SA and SC findings, dosage adjustment for patients receiving CRRT will be required."	( Ertapenem clearance during modeled continuous renal replacement therapy. Churchwell, MD; Depestel, DD; Jakob, V; Kinzig, M; Mueller, BA; Patel, JH; Sörgel, F; Stevenson, JM; Vilay, AM, 2008)	1.79
"Children younger than 12 years require dosing more frequently than once daily to achieve optimal efficacy when treating organisms with a minimum inhibitory concentration near the susceptibility breakpoint."	( Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Abdel-Rahman, SM; Blumer, JL; Groff, M; Herman, G; Jacobs, RF; Kearns, GL; Kitchen, CJ; Majumdar, A; Mistry, GC; Topelberg, S; Wagner, JA; Xu, Y, 2010)	0.6
" The use of higher doses and less-frequent dosing of existing agents is being explored, and exciting new developments include the emergence of agents with broader-spectrum activity against drug-resistant organisms and the use of antifungal agents in the OPAT setting."	( Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. Chapman, AL; Lessing, MP; Sanderson, F; Seaton, RA; Török, ME, 2010)	0.36
" Patient 1 developed garbled speech and miosis 1 week after starting appropriately dosed ertapenem (1 g/day) for sacral osteomyelitis."	( Central nervous system toxicity associated with ertapenem use. Duquaine, S; Kitchell, E; Tannen, RC; Tate, T; Wickremasinghe, IM, 2011)	0.85
") every 24 h (q24h) would achieve concentrations in excess of the MIC for 40% of the dosing interval (40% T>MIC, where T is time) in the serum and peritoneal cavity."	( Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Cardone, KE; Daoui, R; Drusano, GL; Grabe, DW; Kulawy, RW; Lodise, TP; Meola, S; Roglieri, J, 2012)	1.82
"5 h (35% of the dosing interval) after administration of 1 g intravenously."	( Pharmacokinetics of ertapenem in colorectal tissue. Brockschmidt, C; Bulitta, JB; Burhenne, H; Henne-Bruns, D; Isenmann, R; Kaever, V; Mayer, B; Scheele, J; Wittau, M, 2011)	0.69
"73 m2, our 2 cases highlight that this dosage might be excessive for patients with Stage 5 CKD, especially those not yet on dialysis."	( Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Chau, T; Lin, SH; Sung, CC; Wen, MJ, 2013)	0.63
" Ertapenem is a unique drug in that current dosing recommendations call for a 1 g dose for normal renal function patients, despite body weight."	( Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma. Brown, S; Pickering, M, 2013)	1.52
" For bacterial pathogens with an MIC of 1 mg/L, the free mean 'time above MIC' (T>MIC) in the interstitium of infected tissue was calculated to be 38%± 25% of the 24 h dosing interval."	( Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. Burian, A; Burian, B; Höferl, M; Jäger, W; Riedl, M; Sauermann, R; Stella, A; Theurer, S; Zeitlinger, M, 2013)	0.69
" A 5000-subject Monte Carlo simulation was used to assess the probability of target attainment for free drug concentration remaining above the minimum inhibitory concentration (MIC) for 40% or greater of the dosing interval (40% fT > MIC) over an MIC range."	( Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Housman, ST; Kuti, JL; Nicolau, DP; Quintiliani, R; Wiskirchen, DE, 2013)	0.63
" Higher dosage did not prevent selection of porin-deficient subpopulations."	( Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. Adler, M; Cars, O; Löwdin, E; Sandegren, L; Tängdén, T, 2013)	0.59
" An improper perioperative antibiotic use can expose patients to the risk of resistant microorganisms, and, in surgical obese patients, the drug dosage and infusion time are critical points."	( Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs. Catania, MR; Cerbone, D; de Werra, C; Di Micco, R; Forestieri, P; Formato, A; Lambiase, A; Montella, E; Pilone, V, 2013)	0.64
" In the elderly, dosing regimen adaptations are not recommended."	( Population pharmacokinetics of ertapenem in juvenile and old rats. Boulamery, A; Bruguerolle, B; Marsot, A; Simon, N, 2014)	0.69
"The objective of this case report is to report a patient with moderate renal impairment who developed ertapenem-induced encephalopathy with delayed recovery of up to 2 weeks despite receiving and appropriately adjusted dosage of ertapenem."	( Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Cheng, KC; Chu, LW; Hon, FK; Mok, MY; Shea, YF, 2013)	0.92
" A Monte Carlo simulation was performed to estimate the probability of achieving free drug levels above the minimum inhibitory concentration (fT>MIC) for at least 20% and 40% of the dosing interval as PK/PD targets."	( Use of the parenteral antibiotic Ertapenem as short term prophylaxis in bariatric surgery: a pharmaco-kinetic-pharmacodynamic study in class III obese female patients. Accetta, G; Adembri, C; Berti, J; Biggeri, A; Borracci, T; Cappellini, I; De Gaudio, AR; Lucchese, M; Novelli, A, 2014)	0.68
" In view of its dosing convenience, it is increasingly used as outpatient therapy."	( Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Fisher, DA; Hee, KH; Lee, LS; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Zhou, J, 2014)	0.73
" At steady-state, blood and urine samples were collected over one dosing interval."	( Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Fisher, DA; Hee, KH; Lee, LS; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Zhou, J, 2014)	0.73
" A high ertapenem concentration (>128 mg/L) could be attained in the urine at 40% of the dosing interval."	( Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Fisher, DA; Hee, KH; Lee, LS; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Zhou, J, 2014)	1.16
" The in vitro pharmacodynamic model was inoculated with ∼1 × 10(6) cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate free (ƒ) Cmax and t½ obtained after either 1 g or 2 g intravenous once-daily doses in healthy volunteers (1 g: ƒCmax 15 mg/L, t½ 4 h)."	( Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. Adam, HJ; Denisuik, A; Hoban, DJ; Vashisht, S; Yachison, C; Zhanel, GG, 2014)	0.92
" Design and synthesis, in vitro and in vivo evaluation of diversified prodrugs of ertapenem, one of the only once daily dosed carbapenems is described."	( Design, synthesis, and evaluation of prodrugs of ertapenem. Bradley, P; Cama, L; Hafey, MJ; Ji, C; Meinke, PT; Nicoll-Griffith, DA; Olsen, DB; Rindgen, D; Singh, SB; Soll, R; Sun, W; Suzuki, T; Wang, L; Wang, N; Wu, H; Yu, H; Zhang, B, 2013)	0.87
" The diethyl ester prodrug showed the best total absorption (>30%) by intredeudenal dosing in dogs, which could potentially be improved by formulation development."	( Design, synthesis, structure-function relationship, bioconversion, and pharmacokinetic evaluation of ertapenem prodrugs. Bradley, P; Ji, C; Meinke, PT; Nicoll-Griffith, DA; Olsen, DB; Rindgen, D; Singh, SB; Soll, RM; Suzuki, T; Wang, L; Wang, N; Wu, H; Yu, H; Zhang, B, 2014)	0.62
" However, because most published carbapenems studies have excluded patients on dialysis, little is known about the dosing of ertapenem to avoid central nervous system (CNS) toxicity in regular HD patients."	( The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. Chou, YC; Lee, KH; Ng, YY; Ueng, YF; Wu, CW; Yang, WC, 2015)	0.93
" The recommended dosage of 500 mg ertapenem daily may be still too high in regular HD patients, especially in Asians, owing to their relatively small body size."	( The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. Chou, YC; Lee, KH; Ng, YY; Ueng, YF; Wu, CW; Yang, WC, 2015)	1
" The effectiveness of current dosing schemes of ertapenem in subjects with significant hypoalbuminemia should be revisited."	( Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. Daitch, V; Farbman, L; Lador, A; Leibovici, L; Paul, M; Tredler, Z; Zusman, O, 2015)	0.9
" Common dosage regimens were oral dose of 3 g fosfomycin every 72 h (62%), oral dose of 3 g fosfomycin every 48 h (23%) and intravenous dose of 1 g ertapenem daily (76%)."	( Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Davis, SL; Grunwald, JL; Kenney, RM; Veve, MP; Wagner, JL, 2016)	0.93
" Its dosing convenience renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favour its use against complicated urinary tract infections (cUTIs)."	( Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. Archuleta, S; Chan, M; Fisher, DA; Llorin, RM; Lye, DC; Sulaiman, Z; Tam, VH; Tan, SY; Trad, MA; Zhong, LH, 2017)	1.9
" Intraprostatic concentrations were considered satisfactory when higher than the MIC90 value of urinary-targeted pathogens perioperatively and for 40% of the dosing interval."	( Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-centre prospective experience and clinical implications-the ERTAPRO study. Amin, A; Bourget, P; Dariane, C; De Toma, C; Lalli, A; Le Guilchet, T; Lortholary, O; Méjean, A; Michel, C; Nguyen-Khoa, T; Timsit, MO; Treluyer, JM; Urien, S, 2016)	0.7
" coli during exposure to ertapenem and to predict bacterial killing following different dosing regimens of ertapenem."	( A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure. Nielsen, EI; Sandegren, L; Tängdén, T; Ungphakorn, W, 2016)	0.95
" Results from predictions suggest that the conventional dosage (1 g intravenously once daily) might result in regrowth of resistant subpopulations when used to treat infection caused by ESBL-producing strains."	( A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure. Nielsen, EI; Sandegren, L; Tängdén, T; Ungphakorn, W, 2016)	0.64
" coli when exposed to ertapenem, supporting that the time course of emergence of resistance should be taken into consideration when selecting dosing regimens."	( A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure. Nielsen, EI; Sandegren, L; Tängdén, T; Ungphakorn, W, 2016)	0.96
"0 g every 24 hours, for a minimum of four 24-hour dosing cycles."	( Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. Evans, D; Horn, P; Lee, P; Marsh, A; Slepavicius, A; Solomkin, J; Sutcliffe, JA; Tsai, L, 2017)	0.7
" Then, simulations were performed based on the final model to investigate the influence of ertapenem route of administration, dosage and renal function on the probability of achieving a pharmacodynamic (PD) target, defined as the percentage of time for which free plasma concentrations of ertapenem remained above the MIC (fT>MIC) of 40%."	( Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. Chidiac, C; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Valour, F, 2018)	0.94
" Ertapenem, which is popular among clinicians due to its convenient once-daily dosing schedule and favorable safety and tolerability profile, remains highly active against Enterobacteriaceae from IAI and UTI, even as ESBLs and other resistance mechanisms limit therapeutic options, but continued susceptibility testing for surveillance and individual patients is important."	( Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016. Hackel, MA; Hoban, DJ; Lob, SH; Motyl, MR; Sahm, DF; Young, K, 2018)	1.77
"Ertapenem is used off-label to treat osteoarticular infections but there are few pharmacokinetic (PK) data to guide optimal dosing strategies in patients who may be obese with multiple co-morbidities including diabetes and peripheral vascular disease."	( Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. Batty, KT; Chambers, J; Davis, TME; Dyer, J; Manning, L; Page-Sharp, M; Salman, S, 2019)	3.4
"Local bone and free plasma concentrations appear adequate for osteoarticular infections where Enterobacteriaceae are the main causative pathogens, but for Staphylococcus aureus and other bacteria, conventional dosing may lead to inadequate PTA."	( Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations. Batty, KT; Chambers, J; Davis, TME; Dyer, J; Manning, L; Page-Sharp, M; Salman, S, 2019)	1.96
" These results could help to determine if there is a need for altered dosing regimens in the future."	( Modeling Ertapenem: the impact of body mass index on distribution of the antibiotic in the body. Bobola, V; Forbes, W; Frazier, W; Joyner, ML; Manning, CC, 2019)	0.93
"4% and 0% were susceptible standard dosing regimen (S), 55."	( Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli. Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM, 2019)	0.51
" The secondary objective was to review the literature and discuss a safer/cost-effective dosing strategy based on available data."	( Ertapenem Neurotoxicity in Hemodialysis Patients-Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review. Attallah, NM; El Nekidy, WS; Elrefaei, H; Ghazi, IM; Kablaoui, F; Nusair, A; Phillips, J; Piechowski-Jozwiak, B; St John, TJL, 2021)	2.06
" Ampicillin's inconvenient dosing schedule, drug instability, allergy potential, along with ceftriaxone's high risk for Clostridioides difficile infection and its promotion of vancomycin-resistant enterococci (VRE), led our team to explore alternative options."	( Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB, 2022)	0.72
" It also highlights that renal dosing in CKD 5D patients' needs to be clinically studied to ensure antibiotic safety."	( Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report. Arimuthu, DA; Mazlan, SA; Shahar, S, 2022)	2.16

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
carbapenemcarboxylic acid
pyrrolidinecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Aeromonas allosaccharophila	Km	7.0000	1.5000	6.3000	10.0000	AID584846
Beta-lactamase class B VIM-2	Pseudomonas aeruginosa	Km	9.0000	2.0000	6.6500	9.4000	AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1515)

Assay ID	Title	Year	Journal	Article
AID341614	Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P62 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID542382	Reduction of OmpK35 expression in Klebsiella pneumoniae M expressing CTX-M3 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID433020	Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534414	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523571	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574023	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID520807	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype A by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID523738	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E450	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576331	Antibacterial activity against plasmid-mediated AmpC beta-Lactamase DHA-1 and ESBL-producing Klebsiella pneumoniae by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID285999	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 259 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523952	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID341616	Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P62 infected in sc dosed CF1 mouse with high-density bacterial colonization administered daily for 9 days assessed as suppression of stool bacterial count	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID425093	Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID521484	Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID573796	Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425319	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID558799	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID584486	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae ATCC 138821 by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID433150	Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573591	Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID428272	Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID576330	Antibacterial activity against ESBL-producing Klebsiella pneumoniae by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID249288	Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range=0.008-1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID558594	Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID563969	Antibacterial activity against Escherichia coli J53 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID529483	Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID583018	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID498819	Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533380	Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID498804	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID548243	Antibacterial activity against beta-lactamase ESBL-producing Klebsiella sp. assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID522025	Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285987	Antimicrobial activity against ESBL producing Escherichia coli 133 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID563968	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID286017	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 225 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID524325	Antibacterial activity against Acinetobacter baumannii A908 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524408	Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID523922	Antibacterial activity against Acinetobacter baumannii A894 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576310	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID542368	Reduction of OmpK36 expression in wild type Klebsiella pneumoniae M at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID523598	Antibacterial activity against Pseudomonas aeruginosa P338 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285998	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 254 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495907	Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID523893	Antibacterial activity against Pseudomonas aeruginosa P349 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529488	Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID520803	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-2	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID286035	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 257 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523540	Antibacterial activity against beta-lactamase-negative Escherichia coli E348 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524081	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P334	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285985	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 60 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523945	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498809	Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524286	Antibacterial activity against Pseudomonas aeruginosa P332 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583096	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID571018	Antimicrobial activity against Escherichia coli ATCC 25922 assessed as maximum killing rate constant	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID249345	Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=1-128)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID524306	Antibacterial activity against Pseudomonas aeruginosa P370 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID587732	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID509025	Clearance in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID524090	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P363	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID249359	Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range=0.008-1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID368753	Antimicrobial activity against Klebsiella pneumoniae Kp5 expressing plasmid-mediated cephalosporinase ACC-1 and TEM-1	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID523575	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576527	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008137 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523719	Antibacterial activity against Acinetobacter baumannii A891 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520981	Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID524281	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559820	Antimicrobial activity against Escherichia coli J53 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID523727	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E348	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524280	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425101	Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID576538	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008026 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID533393	Antimicrobial activity against Clostridium innocuum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID495793	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID425081	Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID528787	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID562947	Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID433200	Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524089	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P349	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425331	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID542585	Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID495837	Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523912	Antibacterial activity against Acinetobacter baumannii A896 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286039	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 261 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495904	Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID529499	Antimicrobial activity against Escherichia coli GeneHogs by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID558807	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID424328	Antimicrobial activity against Dialister invisus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID586231	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID425075	Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID544489	Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID573582	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID432999	Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID283400	Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID547996	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID576322	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID368742	Antimicrobial activity against Escherichia coli Ec4 expressing CTX-M-1 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID548040	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID584500	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj5 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID547992	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID322776	Antimicrobial activity against Bacteroides thetaiotaomicron isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID563966	Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID524278	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524083	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P338	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573572	Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID584501	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj5 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID588127	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID574469	Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID535755	Antimicrobial activity against community-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID519287	Antimicrobial activity against Acinetobacter radioresistens isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425096	Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID558592	Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID520779	Antibacterial activity against Escherichia coli EC600 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID558813	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID495797	Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID542353	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M9 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID523556	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523939	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID567465	Antimicrobial activity against xtended-spectrum-beta-lactamase-producing Escherichia coli obtained from urinary tract infection patient assessed as percent susceptible isolates by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
AID545655	Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID285688	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID498812	Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533128	Antimicrobial activity against Bacteroides caccae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433174	Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID542370	Antibacterial activity against Escherichia coli Wi expressing CTX-M3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID322775	Antimicrobial activity against Bacteroides ovatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID574472	Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID523758	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523731	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E458	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286006	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 261 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID286024	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 265 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID772162	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID529482	Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524309	Antibacterial activity against Pseudomonas aeruginosa P376 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533365	Antimicrobial activity against Bacteroides uniformis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID533405	Antimicrobial activity against Clostridium tertium by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573799	Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID433354	Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523757	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533361	Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574050	Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID428266	Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID574041	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573595	Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524323	Antibacterial activity against Acinetobacter baumannii A896 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542383	Reduction of OmpK35 expression in Klebsiella pneumoniae M expressing CTX-M9 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID495805	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID495819	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID529490	Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID425084	Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID574034	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID524293	Antibacterial activity against Pseudomonas aeruginosa P322 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576287	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID548004	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID533126	Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573801	Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID520811	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype E by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID545458	Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID286008	Antimicrobial activity against Escherichia coli 120 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523418	Antibacterial activity against beta-lactamase-negative Escherichia coli E345 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523732	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E412	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542372	Antibacterial activity against Escherichia coli Wi expressing CTX-M15	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID523942	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433169	Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID429078	Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID523915	Antibacterial activity against Acinetobacter baumannii A898 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286012	Antimicrobial activity against ESBL producing Escherichia coli 310 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523745	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E465	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574463	Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID521997	Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534409	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584497	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj3 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID499046	Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521996	Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID433353	Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID424319	Antimicrobial activity against Dialister pneumosintes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID433156	Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID286032	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 259 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID533373	Antimicrobial activity against Bacteroides eggerthii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573783	Antibacterial activity against Prevotella buccae by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID535757	Antimicrobial activity against community-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID433012	Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425328	Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495840	Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID425082	Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID531318	Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID524298	Antibacterial activity against Pseudomonas aeruginosa P338 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID565199	Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID368735	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID558792	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID523770	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573785	Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425089	Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID432990	Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID286014	Antimicrobial activity against ESBL producing Escherichia coli 318 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID542378	Reduction of OmpF expression in Escherichia coli Wi expressing CTX-M3 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID573563	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID520780	Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID545440	Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID524307	Antibacterial activity against Pseudomonas aeruginosa P341 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425100	Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523548	Antibacterial activity against beta-lactamase-negative Escherichia coli E424 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542361	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M3 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID495791	Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1296369	Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as efficiency of acylation reaction by measuring ratio of K2 to Kapp by stopped-flow spectrofluorimetric method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID433194	Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID545428	Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID425116	Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID499073	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433351	Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID522009	Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523729	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E408	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425091	Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID498802	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523566	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520967	Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID433165	Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523772	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524405	Antibacterial activity against carbapenemase-producing Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID523726	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E347	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584494	Antibacterial activity against porin deficient OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID433157	Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433007	Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520802	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype J by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID509022	Tmax in patient with bacterial infection at 1 gm/kg, sc administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID542359	Reduction of OmpK36 expression in wild type Klebsiella pneumoniae M at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID584487	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID523925	Antibacterial activity against beta-lactamase-negative Escherichia coli E344 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533400	Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID424321	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID573565	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID529456	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID495816	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523573	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534713	Plasma protein binding in human at 1 g/kg by HPLC method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID368737	Antimicrobial activity against Escherichia coli Ec1 containing pEc1-A plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID583025	Antimicrobial activity against Escherichia coli TOP10 transformed by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID521284	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype H by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID533396	Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID559819	Antimicrobial activity against Escherichia coli J53 harboring pCHE-B plasmid expressing blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID573802	Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498814	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524111	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A898	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523733	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E415	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID772174	Apparent permeability of the compound in pig LLC-PK1 cells	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID286015	Antimicrobial activity against ESBL producing Escherichia coli 243 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID571003	Binding affinity to human serum albumin in THB medium containing 40 g/L HSA	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID571021	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 assessed as growth rate constant	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID498806	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433003	Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521485	Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID533372	Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID521486	Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID772157	AUC (0 to 8 hrs) in Beagle dog at 1 mg/kg, iv	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID433155	Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425079	Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID542369	Antibacterial activity against Escherichia coli Wi expressing CTX-M2	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID286023	Antimicrobial activity against ESBL producing Escherichia coli 130 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523742	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E459	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528784	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID523955	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425103	Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573822	Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523941	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534408	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523914	Antibacterial activity against Acinetobacter baumannii A908 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286037	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 262 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID583098	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID535697	Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID425115	Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID587500	Antibacterial activity against drug-resistant Citrobacter freundii isolate producing metallo-beta-lactamase NDM-1 with carbapenemase activity isolated from urine culture of cerebral vascular malformation patient	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India.
AID562741	Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID574032	Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID562759	Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID278088	Inhibition of growth in Vancomycin-resistant Enterococci C68 by mouse colonization study	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID521995	Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID322778	Antimicrobial activity against Bacteroides vulgatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID433006	Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID584496	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj3 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID279816	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID573823	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524116	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A885	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534600	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535753	Antimicrobial activity against community-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID573551	Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498837	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID368749	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID520975	Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID573552	Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID322792	Antimicrobial activity against Bacteroides stercoris assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID535756	Antimicrobial activity against hospital-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID432998	Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID547785	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID524103	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A912	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576528	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14474 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID425112	Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID548012	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID558591	Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID249282	Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range = 0.008-0.12)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID545658	Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID425087	Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID528920	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID522021	Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573597	Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID433369	Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433161	Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521283	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype G by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID576269	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID523773	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P332	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533425	Antimicrobial activity against Peptostreptococcus sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID532893	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID524113	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A897	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584846	Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID523923	Antibacterial activity against Acinetobacter baumannii A901 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523560	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523559	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573593	Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498827	Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID322783	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID571008	Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method in presence of 40 g/L human serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524311	Antibacterial activity against Acinetobacter baumannii A848 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533376	Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433002	Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID368745	Antimicrobial activity against Escherichia coli Ec8 expressing TEM-21 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID425110	Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID574462	Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID285988	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 101 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433368	Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532898	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID432994	Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID530816	Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID425102	Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433004	Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524073	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P369	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433179	Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533131	Antimicrobial activity against Bacteroides fragilis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID499048	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523550	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1225790	Antibacterial activity against Klebsiella pneumoniae KP1084 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID574465	Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID499063	Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524084	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P328	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546620	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID563967	Antibacterial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID542379	Reduction of OmpF expression in Escherichia coli Wi expressing CTX-M9 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID499072	Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID286010	Antimicrobial activity against ESBL producing Escherichia coli 321 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID368746	Antimicrobial activity against Escherichia coli Ec9 expressing TEM-24b TEM-26 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID523561	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573592	Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574027	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524082	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P337	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576323	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008226 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID498823	Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519293	Antimicrobial activity against Escherichia coli TOP10 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID533413	Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID542364	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M2 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID571025	Antimicrobial activity against Escherichia coli ATCC 25922	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID558596	Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID520970	Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID368747	Antimicrobial activity against Escherichia coli Ec10 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID524275	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524268	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285977	Antimicrobial activity against ESBL producing Escherichia coli 321 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523895	Antibacterial activity against Pseudomonas aeruginosa P370 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID322777	Antimicrobial activity against Bacteroides uniformis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID425320	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523931	Antibacterial activity against beta-lactamase-negative Escherichia coli E408 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571027	Antimicrobial activity against Escherichia coli ATCC 25922 by in presence of human serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID523921	Antibacterial activity against Acinetobacter baumannii A891 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524119	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A901	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499057	Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433014	Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID340726	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-15 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID433371	Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID432997	Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573394	Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524100	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A851	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573557	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498360	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52145R assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID340727	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-2 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID573824	Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID509021	Tmax in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID523735	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E424	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547761	Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID523908	Antibacterial activity against Acinetobacter baumannii A892 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528788	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID576535	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080792 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID433196	Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533385	Antimicrobial activity against Clostridium difficile by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433000	Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID523759	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524295	Antibacterial activity against Pseudomonas aeruginosa P323 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433154	Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425109	Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523926	Antibacterial activity against beta-lactamase-negative Escherichia coli E345 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524407	Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID495843	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523928	Antibacterial activity against beta-lactamase-negative Escherichia coli E347 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576543	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008027 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523736	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E425	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495913	Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID533631	Antimicrobial activity against Propionibacterium acnes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523751	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E360	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433011	Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID341594	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID523924	Antibacterial activity against Acinetobacter baumannii A903 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID425094	Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573397	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534410	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433019	Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID498817	Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID544491	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID433375	Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID498841	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID424324	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID523750	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E359	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534411	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425108	Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID548016	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID499054	Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533389	Antimicrobial activity against Clostridium perfringens by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID283396	Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID433168	Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID498842	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID588131	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID285975	Antimicrobial activity against Escherichia coli 120 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID534412	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID368750	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 TEM-17 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID571006	Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID563970	Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID565200	Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID428267	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID533417	Antimicrobial activity against Micromonas micros by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID425085	Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID322786	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID433163	Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID586233	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID521488	Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID285994	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 260 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID544490	Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID425120	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID542377	Reduction of OmpF expression in Escherichia coli Wi expressing CTX-M2 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID1225788	Antibacterial activity against Klebsiella pneumoniae KP1087 expressing KPC2/CTX-M-15/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID425092	Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID285980	Antimicrobial activity against ESBL producing Escherichia coli 312 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID533409	Antimicrobial activity against Finegoldia magna by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID425086	Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524097	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A850	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521992	Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573819	Antibacterial activity against Veillonella parvula by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID533369	Antimicrobial activity against Bacteroides vulgatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID322779	Antimicrobial activity against Bacteroides caccae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID322791	Antimicrobial activity against Bacteroides merdae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID588130	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID495911	Antimicrobial activity in Escherichia coli J53 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID340729	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-14 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID524074	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P373	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583015	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID433159	Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523582	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523734	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E437	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545431	Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID495802	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID534415	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID286007	Antimicrobial activity against Escherichia coli ATCC 25922 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523723	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E344	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495908	Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID586234	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID576281	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID524317	Antibacterial activity against Acinetobacter baumannii A911 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498839	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520980	Antibacterial activity against Klebsiella pneumoniae YC by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523568	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1296370	Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli by spectrophotometric method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID340730	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase TEM-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID433370	Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523934	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542363	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M15 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID584837	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID498872	Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID433153	Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID322774	Antimicrobial activity against Bacteroides distasonis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID529495	Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID562758	Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID433198	Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499050	Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521286	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype J by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID495909	Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID542374	Antibacterial activity against Klebsiella pneumoniae M expressing CTX-M3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID495809	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID498838	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425317	Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495798	Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID523919	Antibacterial activity against Acinetobacter baumannii A890 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533381	Antimicrobial activity against Bacteroides nordii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573590	Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID424331	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID524088	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P340	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546621	Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID523935	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID498808	Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523954	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535694	Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID495828	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID286029	Antimicrobial activity against ESBL producing Escherichia coli 311 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID522018	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID323868	Induction of mecA/16S rRNA ratio in methicillin-resistant Staphylococcus aureus ATCC 33591 at 0.5 times MIC at pH 7.4 after 5 hrs	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID584493	Antibacterial activity against porin deficient OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID433005	Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID285992	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 268 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID323660	Antibacterial activity against Peptostreptococcus stomatis	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
AID524118	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A894	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID278089	Inhibition of growth in Klebsiella pneumoniae P62 by mouse colonization study	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID425077	Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523593	Antibacterial activity against Pseudomonas aeruginosa P322 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433167	Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID548028	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID425088	Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID576292	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID524095	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P326	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571029	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 in presence of bovine serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID495834	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524096	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A848	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433162	Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523946	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533421	Antimicrobial activity against Anaerococcus prevotii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID324312	Antimicrobial activity against Serratia marcescens AW isolated from parotidectomy patient	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SME-2-producing Serratia marcescens isolate from Switzerland.
AID520971	Antibacterial activity against Klebsiella pneumoniae 633 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID433152	Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533635	Antimicrobial activity against Propionibacterium sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID544493	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID523570	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433173	Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1225784	Antibacterial activity against Klebsiella oxytoca KX1017 expressing KPC2/OXA2/SHV30 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID523717	Antibacterial activity against Acinetobacter baumannii A890 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583028	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID529194	Antibacterial activity against AmpC-producing Escherichia coli isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID561441	Antibacterial activity against Escherichia coli 1285 harboring beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID565197	Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID588126	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID523715	Antibacterial activity against Acinetobacter baumannii A897 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533428	Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523417	Antibacterial activity against beta-lactamase-negative Escherichia coli E344 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425114	Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID542351	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M2 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID524115	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A890	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533135	Antimicrobial activity against Bacteroides ovatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523749	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E358	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498813	Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559818	Antimicrobial activity against Escherichia coli J53 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID432996	Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523747	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E484	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533125	Antimicrobial activity against Bacteroides distasonis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID533401	Antimicrobial activity against Clostridium subterminale by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID499049	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID588123	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID522022	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID542354	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M15 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID425097	Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID322780	Antimicrobial activity against Bacteroides eggerthii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID425090	Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID567466	Antimicrobial activity against xtended-spectrum-beta-lactamase-producing Escherichia coli obtained from urinary tract infection patient by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
AID563602	Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID532907	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID432993	Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID278092	Drug level in mouse stool after 3 days	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID531313	Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID523947	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID509028	fT>MIC methicillin-resistant Escherichia coli-infected kinetic model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID286013	Antimicrobial activity against ESBL producing Escherichia coli 312 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID522000	Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID545437	Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID495808	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID424329	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID529494	Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524079	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P327	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542355	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M2 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID573564	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524076	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P319	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523542	Antibacterial activity against beta-lactamase-negative Escherichia coli E408 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523595	Antibacterial activity against Pseudomonas aeruginosa P323 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523588	Antibacterial activity against Pseudomonas aeruginosa P369 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523918	Antibacterial activity against Acinetobacter baumannii A929 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523766	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530815	Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID524318	Antibacterial activity against Acinetobacter baumannii A912 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574470	Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID425095	Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID341597	Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID433010	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523748	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E357	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID509027	fT>MIC methicillin-resistant Haemophilus pneumonia-infected kinetic model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID519292	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-105 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID522012	Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID323659	Antibacterial activity against Peptostreptococcus anaerobius	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
AID283397	Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID523587	Antibacterial activity against Pseudomonas aeruginosa P356 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519289	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-23 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID576266	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID563598	Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolates by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
AID576522	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS080884 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID520797	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype E by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID523589	Antibacterial activity against Pseudomonas aeruginosa P373 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584489	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID533377	Antimicrobial activity against Bacteroides merdae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID285689	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID286020	Antimicrobial activity against ESBL producing Escherichia coli 133 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433001	Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521994	Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524322	Antibacterial activity against Acinetobacter baumannii A884 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524312	Antibacterial activity against Acinetobacter baumannii A850 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521837	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID425099	Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433158	Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID547777	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID433192	Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID286031	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 254 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID498826	Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425076	Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433376	Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495903	Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID573786	Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID433149	Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534413	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433355	Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID283391	Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID523901	Antibacterial activity against Acinetobacter baumannii A850 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285990	Antimicrobial activity against ESBL producing Escherichia coli 130 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID548234	Antibacterial activity against beta-lactamase CTX-M ESBL-producing Enterobacteriaceae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID524300	Antibacterial activity against Pseudomonas aeruginosa P352 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498820	Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425078	Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID529458	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID576519	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS081058 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523558	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433160	Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573581	Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495831	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID583097	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID587728	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID499065	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID547769	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID283322	Antimicrobial activity against Escherichia coli XL10/pSHV-31	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID424332	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID523553	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433356	Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1296371	Activity at Mycobacterium tuberculosis beta lactamase BlaC expressed in Escherichia coli assessed as ratio of Kcat to Km by spectrophotometric method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID583653	Antibacterial activity against Escherichia coli TOP10	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID523541	Antibacterial activity against beta-lactamase-negative Escherichia coli E350 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573784	Antibacterial activity against Prevotella bivia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID278093	Drug level in mouse stool after 5 days	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID524308	Antibacterial activity against Pseudomonas aeruginosa P358 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534711	Half life in human at 1 g/kg by HPLC method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID584838	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID584839	Antimicrobial activity against Escherichia coli DH10B by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID533134	Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523900	Antibacterial activity against Acinetobacter baumannii A848 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID432992	Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID544496	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID520801	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype I by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID558786	Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID425083	Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524310	Antibacterial activity against Pseudomonas aeruginosa P326 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522002	Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID576295	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495804	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID533412	Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523592	Antibacterial activity against Pseudomonas aeruginosa P320 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544497	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID532904	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID576060	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID368741	Antimicrobial activity against Escherichia coli Ec3 expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID368756	Antimicrobial activity against Enterobacter cloacae Ecl1 expressing TEM-24b AmpC TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID523752	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E419	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524284	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559822	Antimicrobial activity against Pseudomonas aeruginosa PU21 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID523564	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523739	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E452	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574473	Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID524105	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A849	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID588132	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID574460	Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID573596	Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID772170	AUC (0 to 8 hrs) in Sprague-Dawley rat at 10 mg/kg, po	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID523576	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433166	Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID529195	Antibacterial activity against ESBL-producing Escherichia coli assessed as sensitive isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID584835	Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID573795	Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524287	Antibacterial activity against Pseudomonas aeruginosa P356 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520778	Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID424322	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID574026	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524110	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A908	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574459	Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID573574	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID531315	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID533130	Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID524086	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P353	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584491	Antibacterial activity against porin, OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID529492	Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID523898	Antibacterial activity against Pseudomonas aeruginosa P376 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498811	Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID498822	Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523584	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523730	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E409	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546623	Ratio of MIC for Escherichia coli harboring beta-lactamase VIM-2 to MIC for Escherichia coli harboring beta-lactamase VIM-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID322781	Antimicrobial activity against Bacteroides stercoris isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID584847	Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID433164	Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID583093	Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID322789	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID563971	Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID548244	Antibacterial activity against beta-lactamase ESBL-producing Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID523563	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID279813	Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID529489	Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID340728	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-9 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID521993	Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID432995	Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433017	Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID522011	Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID583651	Antibacterial activity against Escherichia coli isolate 271	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID573834	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID428268	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID433015	Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425104	Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID520973	Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID533397	Antimicrobial activity against Clostridium paraputrificum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID576272	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1296367	Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as first order rate constant for oxyanion formation by stopped-flow spectrofluorimetric method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID521490	Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID340725	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-1 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID523920	Antibacterial activity against Acinetobacter baumannii A885 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583019	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID576063	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID425117	Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID522005	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID545464	Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID524099	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A865	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532900	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID523728	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E350	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524101	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A867	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425080	Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID529196	Antibacterial activity against ESBL-producing Escherichia coli isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID425121	Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523769	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574461	Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID499052	Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID542360	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M2 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID542376	Antibacterial activity against Klebsiella pneumoniae M expressing CTX-M15	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID424320	Antimicrobial activity against Dialister micraerophilus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID571002	Protein binding in pooled human plasma by microdialysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID523581	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524314	Antibacterial activity against Acinetobacter baumannii A865 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532905	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID532895	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID529461	Antimicrobial activity against Escherichia coli J53 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID576520	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070654 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID576284	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID558793	Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID576531	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008139 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID322773	Antimicrobial activity against Bacteroides fragilis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID532910	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID574466	Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID523763	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529460	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID584498	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj3 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID368754	Antimicrobial activity against Proteus mirabilis Pm1-Pm3 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID433361	Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID545425	Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID523940	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID283394	Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID523554	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433151	Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID528921	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID576313	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID425332	Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID520984	Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523927	Antibacterial activity against beta-lactamase-negative Escherichia coli E346 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495803	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID571012	Bactericidal activity against Escherichia coli ATCC 25922 at 8 times MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID523716	Antibacterial activity against Acinetobacter baumannii A929 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576316	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID535754	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID520775	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID529485	Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID433016	Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523713	Antibacterial activity against Acinetobacter baumannii A898 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523722	Antibacterial activity against Acinetobacter baumannii A903 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520805	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-59	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID571026	Antimicrobial activity against Escherichia coli ATCC 25922 in presence of bovine serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID322790	Antimicrobial activity against Bacteroides eggerthii assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID542384	Reduction of OmpK35 expression in Klebsiella pneumoniae M expressing CTX-M15 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID368752	Antimicrobial activity against Klebsiella pneumoniae Kp4 expressing SHV-12 SHV-1 and plasmid-mediated cephalosporinase CMY-4	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID574667	Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID588124	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID498843	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID509019	Cmax in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID528792	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID523944	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285981	Antimicrobial activity against ESBL producing Escherichia coli 118 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID583026	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID498807	Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425105	Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID521841	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID533416	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433008	Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID368739	Antimicrobial activity against Escherichia coli Ec2-a containing pEc1-C plasmid expressing CTX-M-15 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID573825	Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523756	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576521	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081072 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID433360	Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520968	Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID428269	Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID571013	Bactericidal activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 at 8 times MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID574467	Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID498361	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrB containing isogenic acrB knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID523547	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524321	Antibacterial activity against Acinetobacter baumannii A910 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583652	Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID433018	Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID519290	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-102 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID534599	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID499067	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433013	Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433009	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID283320	Antimicrobial activity against Klebsiella pneumoniae KPN15-NL	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID495906	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID322782	Antimicrobial activity against Bacteroides merdae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID524313	Antibacterial activity against Acinetobacter baumannii A864 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583017	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID586236	Antimicrobial activity against Escherichia coli J53 harboring Klebsiella pneumoniae Kp7 beta-lactamase NDM-1	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID547773	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID286027	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 260 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID529491	Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID521487	Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID533368	Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523771	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524316	Antibacterial activity against Acinetobacter baumannii A867 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523578	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546619	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID520969	Antibacterial activity against Klebsiella pneumoniae GR by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID573573	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID286000	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 263 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID571028	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID523910	Antibacterial activity against Acinetobacter baumannii A910 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532909	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID523894	Antibacterial activity against Pseudomonas aeruginosa P363 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498831	Antimicrobial activity against Escherichia coli C600 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584488	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID499060	Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523938	Antibacterial activity against beta-lactamase-negative Escherichia coli E425 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433352	Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533638	Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523902	Antibacterial activity against Acinetobacter baumannii A864 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545455	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID1449634	Protein binding in human plasma at < 50 ug/ml	2017	European journal of medicinal chemistry, May-05, Volume: 131	Recent updates of carbapenem antibiotics.
AID524104	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A892	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523555	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529198	Antibacterial activity against AmpC-producing Escherichia coli assessed as sensitive isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
AID523943	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID283393	Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520966	Antibacterial activity against Klebsiella pneumoniae YC by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID563601	Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID523551	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574005	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574051	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID542371	Antibacterial activity against Escherichia coli Wi expressing CTX-M9	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID523755	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E418	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532903	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID523930	Antibacterial activity against beta-lactamase-negative Escherichia coli E350 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499071	Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523552	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524093	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P358	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574668	Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID534192	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID498844	Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433366	Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524292	Antibacterial activity against Pseudomonas aeruginosa P320 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524297	Antibacterial activity against Pseudomonas aeruginosa P337 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583014	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID341596	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID425318	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID532906	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID562949	Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID322784	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID368743	Antimicrobial activity against Escherichia coli Ec5 expressing CTX-M-2 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID562948	Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID558590	Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID286042	Activity against ESBL producing Klebsiella pneumonia 262 isolate at up to 4 ug/ml	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID546618	Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID524107	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A884	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522006	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID571011	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method in presence of 40 g/L human serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID576529	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008136 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID279815	Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID522007	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID559821	Antimicrobial activity against Pseudomonas aeruginosa PU21 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID558790	Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID368736	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID498810	Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285690	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID523754	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E362	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID249276	Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range=0.008-1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID520799	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype G by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID523724	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E345	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523572	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523545	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558593	Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID586235	Antimicrobial activity against Escherichia coli J53	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID542352	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M3 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID523712	Antibacterial activity against Pseudomonas aeruginosa P340 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524279	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576069	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID574042	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID584502	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj5 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID574468	Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1225789	Antibacterial activity against Klebsiella pneumoniae KP1083 expressing KPC3/SHV-1/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID523585	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID772163	Bioavailability in Sprague-Dawley rat at 10 mg/kg, ID administered as infusion	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID558802	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID528783	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID528916	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID576536	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008138 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID498821	Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID286003	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 258 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID548238	Antibacterial activity against beta-lactamase CTX-M ESBL-producing Enterobacteriaceae assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID532899	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID574052	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID341613	Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolate	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID583024	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID571007	Antimicrobial activity against Escherichia coli ATCC 25922 by serial dilution twofold broth microdilution method in presence of 40 g/L bovine serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID547801	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID521835	Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID523767	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E417	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529462	Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID571004	Binding affinity to pooled adult bovine serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID576324	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008142 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID279812	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID519291	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-103 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID522014	Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523909	Antibacterial activity against Acinetobacter baumannii A849 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523932	Antibacterial activity against beta-lactamase-negative Escherichia coli E409 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523744	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E460	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523591	Antibacterial activity against Pseudomonas aeruginosa P319 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558599	Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID563600	Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID433178	Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID529498	Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524288	Antibacterial activity against Pseudomonas aeruginosa P369 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542362	Reduction of OmpC expression in Escherichia coli Wi expressing CTX-M9 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID535691	Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID498818	Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID425098	Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID583016	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID542356	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M3 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID584495	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj3 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID322785	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID544492	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID524303	Antibacterial activity against Pseudomonas aeruginosa P340 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520976	Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523725	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E346	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285996	Antimicrobial activity against ESBL producing Escherichia coli 311 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID545434	Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID523905	Antibacterial activity against Acinetobacter baumannii A867 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1225783	Antibacterial activity against Klebsiella oxytoca KX1019 expressing KPC2/OXA2 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID574004	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523762	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286018	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 60 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID368733	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b AmpC +/- TEM-1 or TEM-2 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID576275	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID524294	Antibacterial activity against Pseudomonas aeruginosa P327 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID523718	Antibacterial activity against Acinetobacter baumannii A885 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499051	Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID532896	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID529484	Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID584499	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj5 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID524276	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524296	Antibacterial activity against Pseudomonas aeruginosa P334 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531317	Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID433364	Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID498832	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID499055	Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523562	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID428273	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID522187	Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524094	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P376	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID429077	Antibacterial activity against Escherichia coli J53 by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID523933	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498830	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID509018	fT>MIC methicillin-resistant Staphylococcus aureus-infected kinetic model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID522019	Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1225787	Antibacterial activity against Klebsiella pneumoniae KP1082 expressing KPC2/SHV-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID433170	Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533404	Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID542365	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M3 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID588128	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID520800	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype H by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID576307	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID523569	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523601	Antibacterial activity against Pseudomonas aeruginosa P353 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285982	Antimicrobial activity against ESBL producing Escherichia coli 243 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID573800	Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID571019	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 assessed as maximum killing rate constant	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID520977	Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523714	Antibacterial activity against Acinetobacter baumannii A931 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574003	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285984	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 225 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID495822	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523597	Antibacterial activity against Pseudomonas aeruginosa P337 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523937	Antibacterial activity against beta-lactamase-negative Escherichia coli E424 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495842	Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID558783	Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID368748	Antimicrobial activity against Klebsiella pneumoniae Kp1 expressing SHV-4 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID341107	Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID545422	Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID424330	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID565201	Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID524319	Antibacterial activity against Acinetobacter baumannii A892 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562951	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID573583	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524087	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P365	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID428270	Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID498840	Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524117	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A891	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534416	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524098	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A864	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID587730	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID558597	Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID425329	Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID530813	Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID323869	Induction of mecA/16S rRNA ratio in methicillin-resistant Staphylococcus aureus ATCC 33591 at 0.5 times MIC at pH 5.5 after 5 hrs	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.
AID524299	Antibacterial activity against Pseudomonas aeruginosa P328 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523721	Antibacterial activity against Acinetobacter baumannii A901 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286005	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 256 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID535751	Antimicrobial activity against community-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID495838	Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID574006	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID561443	Antibacterial activity against Escherichia coli 34943 harboring beta-lactamase CMY-44 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID548250	Antibacterial activity against beta-lactamase SHV or TEM ESBL-producing Enterobacteriaceae assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID573836	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524302	Antibacterial activity against Pseudomonas aeruginosa P365 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542380	Reduction of OmpF expression in Escherichia coli Wi expressing CTX-M15 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID548241	Antibacterial activity against beta-lactamase ESBL-producing Escherichia coli assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1296368	Inhibition of Mycobacterium tuberculosis LdtMt1 expressed in Escherichia coli assessed as second order rate constant for acylenzyme formation by stopped-flow spectrofluorimetric method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by β-Lactamase BlaC.
AID583020	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID573835	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498805	Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523602	Antibacterial activity against Pseudomonas aeruginosa P365 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523936	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520777	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID523764	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545443	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID498824	Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524304	Antibacterial activity against Pseudomonas aeruginosa P349 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID278094	Overgrowth of vancomycin-resistant enterococci growth in mouse intestine assessed in stool 2 days after 5 days treatment relative to saline	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID584836	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID528917	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID523539	Antibacterial activity against beta-lactamase-negative Escherichia coli E347 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID368759	Antimicrobial activity against Escherichia coli Ec6 expressing CTX-M-14 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID523916	Antibacterial activity against Acinetobacter baumannii A931 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576298	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID520978	Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID573598	Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID565198	Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID524075	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P335	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583095	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID523419	Antibacterial activity against beta-lactamase-negative Escherichia coli E346 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576539	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081042 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523600	Antibacterial activity against Pseudomonas aeruginosa P352 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576072	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID524290	Antibacterial activity against Pseudomonas aeruginosa P335 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285989	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 230 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID576542	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008135 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID498362	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrR containing isogenic acrR knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID524285	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499070	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID583027	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID428274	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID286011	Antimicrobial activity against ESBL producing Escherichia coli 322 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID520793	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype A by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID433367	Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558600	Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID531314	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID587733	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID524271	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425107	Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523737	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E446	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498829	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID558796	Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID573837	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID509020	Half life in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID520795	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype C by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID532913	Antimicrobial activity against Escherichia coli Genehogs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID548242	Antibacterial activity against beta-lactamase ESBL-producing Proteus mirabilis assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID534712	Half life in rhesus monkey at 10 mg/kg by HPLC method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID558589	Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID424327	Antimicrobial activity against Dialister propionicifaciens by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID520794	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype B by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID521489	Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID509023	Half life in patient with bacterial infection at 1 gm/kg, sc administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID534417	Antimicrobial activity against methicillin-susceptible Streptococcus pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID530824	Compound hydrolyzing activity of Klebsiella pneumoniae beta-lactamase OXA-48	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID520979	Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID285974	Antimicrobial activity against Escherichia coli ATCC 25922 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID524080	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P323	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535758	Antimicrobial activity against hospital-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID498825	Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524289	Antibacterial activity against Pseudomonas aeruginosa P373 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286002	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 257 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID524320	Antibacterial activity against Acinetobacter baumannii A849 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529497	Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID576263	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529496	Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524267	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523546	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID548024	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID429080	Activity at Klebsiella pneumoniae Greece Carbapenem-Hydrolyzing-Lactamase KPC-2 assessed per mg of total protein by spectrophotometrically	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID571024	Plasma protein binding in healthy human 1t 1 g/kg, iv administered as single dose by LC-MS-MS method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID561445	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-44 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID542366	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M9 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID524077	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P320	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524270	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524282	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529481	Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524092	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P341	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573798	Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID522008	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID322787	Antimicrobial activity against Bacteroides uniformis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID524108	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A896	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524283	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547789	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID523897	Antibacterial activity against Pseudomonas aeruginosa P358 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573600	Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1225786	Antibacterial activity against Klebsiella pneumoniae KP1008 expressing KPC2 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID286001	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 266 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID522017	Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID574033	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524277	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID368738	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-B plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID425119	Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523580	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID341617	Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P10045 infected in sc dosed CF1 mouse with high-density bacterial colonization administered daily for 9 days assessed as suppression of stool bacterial count	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID524085	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P352	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498816	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433365	Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524269	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562739	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID368757	Antimicrobial activity against Morganella morganii expressing TEM-24b AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID429079	Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID522027	Antimicrobial activity against Escherichia coli isolate J53 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495807	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID571010	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method in presence of 40 g/L bovine serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID574666	Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID433359	Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495910	Antimicrobial activity in Escherichia coli TOP10 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID520796	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae with PFGE pulsotype D by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID548246	Antibacterial activity against beta-lactamase SHV or TEM ESBL-producing Enterobacteriaceae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID433172	Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433190	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521843	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID529487	Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID495825	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID285997	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 255 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523761	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425113	Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID520974	Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID574464	Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID286033	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 263 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433177	Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425111	Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID285978	Antimicrobial activity against ESBL producing Escherichia coli 322 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID283395	Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID499047	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID495839	Ratio of Kcat to Km for Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524078	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P322	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544494	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID522028	Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID772171	AUC (0 to 8 hrs) in Sprague-Dawley rat at 1 mg/kg, iv	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID433193	Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532901	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID278091	Overgrowth of enterococci in mouse intestine assessed in stool after 3 days	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID249355	Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range=0.008-0.12)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID571009	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 by serial dilution twofold broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID523594	Antibacterial activity against Pseudomonas aeruginosa P327 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523906	Antibacterial activity against Acinetobacter baumannii A911 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID499058	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID286025	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 268 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523720	Antibacterial activity against Acinetobacter baumannii A894 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524274	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID428271	Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID558595	Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID571020	Antimicrobial activity against Escherichia coli ATCC 25922 assessed as growth rate constant	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID499062	Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521285	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype I by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID498828	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521999	Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523913	Antibacterial activity against Acinetobacter baumannii A928 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID286016	Antimicrobial activity against ESBL producing Escherichia coli 285 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID368744	Antimicrobial activity against Escherichia coli Ec7 expressing SHV-12 IRT-6 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID545461	Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID542367	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M15 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID498803	Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID498815	Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524102	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A911	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571005	Binding affinity to bovine serum albumin in THB medium containing 40 g/L BSA	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID542375	Antibacterial activity against Klebsiella pneumoniae M expressing CTX-M9	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID498836	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523586	Antibacterial activity against Pseudomonas aeruginosa P332 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID278095	Overgrowth of Klebsiella pneumonia growth in mouse intestine assessed in stool 2 days after 5 day treatment relative to saline	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID520810	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype D by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID529516	Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID523596	Antibacterial activity against Pseudomonas aeruginosa P334 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523953	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID586232	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID285691	Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID561444	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID523565	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571030	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae ATCC 6303 in presence of human serum albumin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Effect of protein binding on the pharmacological activity of highly bound antibiotics.
AID576532	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008143 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID368751	Antimicrobial activity against Klebsiella pneumoniae Kp3 expressing SHV-2a TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID286038	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 256 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID548008	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID433199	Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID286041	Bacteriostasis activity against ESBL producing Klebsiella pneumonia 262 isolate at up to 1.5 ug/ml	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523917	Antibacterial activity against Acinetobacter baumannii A897 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID368758	Antimicrobial activity against Klebsiella oxytoca expressing TEM-11 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID522023	Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID532912	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID584490	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID433201	Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID772173	AUC (0 to 8 hrs) in Sprague-Dawley rat at 10 mg/kg, ID administered as infusion	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID509024	Ratio of AUC (0 to 24 hrs) in sc dosed patient with bacterial infection to AUC (0 to 24 hrs) in iv dosed patient with bacterial infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID524072	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P356	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542358	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M15 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID285979	Antimicrobial activity against ESBL producing Escherichia coli 310 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433176	Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID547793	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID576541	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008141 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523949	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1225781	Antibacterial activity against Escherichia coli EC1007 expressing KPC3 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID533424	Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID533420	Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID283398	Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID558598	Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID283390	Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID522004	Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285993	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 270 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID542584	Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID520982	Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID573797	Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523929	Antibacterial activity against beta-lactamase-negative Escherichia coli E348 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520808	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype B by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID533392	Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID286022	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 230 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID576533	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080949 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID574471	Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID576278	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534194	Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID368740	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-D plasmid expressing CTX-M-15 TEM-1 OXA-1gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID529493	Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID425330	Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID576301	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID521991	Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID535752	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID283392	Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID533634	Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID524291	Antibacterial activity against Pseudomonas aeruginosa P319 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559817	Antimicrobial activity against Enterobacter cloacae CHE-2 harboring blaGES-5 and blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID561446	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-2 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID520776	Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID1449633	Elimination half life in human at 1 g, iv administered as single dose	2017	European journal of medicinal chemistry, May-05, Volume: 131	Recent updates of carbapenem antibiotics.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID561442	Antibacterial activity against Escherichia coli YD006 harboring beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID523544	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1225791	Antibacterial activity against Klebsiella pneumoniae KP1088 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID576540	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080571 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID322788	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID548032	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID530817	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID341108	Antibacterial activity against Escherichia coli 26R793 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID499064	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID532894	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID587731	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID521839	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID523543	Antibacterial activity against beta-lactamase-negative Escherichia coli E409 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523765	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573594	Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524120	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A903	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID587729	Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID495912	Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID425334	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533384	Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID283321	Antimicrobial activity against Escherichia coli XL10/vector	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID286019	Antimicrobial activity against ESBL producing Escherichia coli 315 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID562738	Antimicrobial activity against Escherichia coli K-12 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID523907	Antibacterial activity against Acinetobacter baumannii A912 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522026	Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID425333	Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523574	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576075	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID523903	Antibacterial activity against Acinetobacter baumannii A865 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID548020	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID499053	Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID286028	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 264 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID520798	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype F by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID523590	Antibacterial activity against Pseudomonas aeruginosa P335 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530818	Antibacterial activity against amoxicillin and amoxicillin-clavulanate resistant Klebsiella pneumoniae UCL-1 assessed as zone of inhibition by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID533364	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID521998	Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285991	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 265 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID583029	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID588125	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID499059	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521491	Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID283399	Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID524114	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A929	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523904	Antibacterial activity against Acinetobacter baumannii A851 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520985	Antibacterial activity against Klebsiella pneumoniae 633 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID576304	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID424323	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID340731	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase SHV-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID523549	Antibacterial activity against beta-lactamase-negative Escherichia coli E425 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID498834	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523579	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523583	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID522010	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524324	Antibacterial activity against Acinetobacter baumannii A928 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533388	Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID433197	Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524091	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P370	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID509017	Cmax in patient with bacterial infection at 1 gm/kg, sc administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID547781	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID249275	Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=1-128)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID286009	Antimicrobial activity against ESBL producing Escherichia coli 320 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID576537	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008024 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID524272	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524301	Antibacterial activity against Pseudomonas aeruginosa P353 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523950	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532897	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID522020	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523951	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529486	Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID573599	Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524315	Antibacterial activity against Acinetobacter baumannii A851 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495806	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID522013	Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID520983	Antibacterial activity against Klebsiella pneumoniae GR by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID499061	Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID498845	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID249348	Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range = 0.008-0.1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID286036	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 258 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID341595	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID524273	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533360	Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID341593	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID532902	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID341106	Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID368734	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID587727	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID278090	Inhibition of intestinal colonization of Bacteroides sp in mouse assessed in stool after 3 days relative to saline	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
AID520809	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype C by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID522024	Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID545449	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID542357	Reduction of OmpK36 expression in Klebsiella pneumoniae M expressing CTX-M9 at 4 times MIC concentration by SDS-PAGE analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID529463	Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID562950	Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID520972	Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID532911	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID573558	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID509029	fT>MIC methicillin-resistant Klebsiella pneumoniae-infected kinetic model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID576523	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008140 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID286030	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 255 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523948	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576524	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070446 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID286034	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 266 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID562737	Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID499056	Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID547765	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID561447	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID524305	Antibacterial activity against Pseudomonas aeruginosa P363 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532908	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID574043	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1225782	Antibacterial activity against Enterobacter cloacae ECL1058 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID499045	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID562760	Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID523567	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433202	Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID542381	Reduction of OmpK35 expression in Klebsiella pneumoniae M expressing CTX-M2 at 4 times MIC concentration by RT-PCR analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID495905	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID285986	Antimicrobial activity against ESBL producing Escherichia coli 315 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID285983	Antimicrobial activity against ESBL producing Escherichia coli 285 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523740	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E456	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID341615	Antibacterial activity against extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae P10045 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
AID1225785	Antibacterial activity against Klebsiella pneumoniae KP1004 expressing KPC2/TEM1/SHV11 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID523746	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E483	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544495	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID495810	Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID425106	Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523743	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E451	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID524106	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A910	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576534	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14358 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523753	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E361	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584492	Antibacterial activity against porin, OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID524112	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A931	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523577	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID548000	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID529457	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID498833	Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID562748	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID544488	Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID562736	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID433357	Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID576526	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008028 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID286021	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 101 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID285976	Antimicrobial activity against ESBL producing Escherichia coli 320 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID425118	Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID547797	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID433195	Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433175	Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499069	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID545452	Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID562740	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID286004	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 262 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID542373	Antibacterial activity against Klebsiella pneumoniae M expressing CTX-M2	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.
AID583030	Antimicrobial activity against Escherichia coli TOP10 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID285995	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 264 isolate	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID523899	Antibacterial activity against Pseudomonas aeruginosa P326 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID368755	Antimicrobial activity against Proteus mirabilis Pm4 expressing TEM-21 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID522001	Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID498835	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523741	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E430	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576525	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate HIP10924 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID531316	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID499068	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID286026	Antimicrobial activity against ESBL producing Klebsiella pneumoniae 270 isolate infected thigh infection model ICR mouse	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
AID433362	Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID545446	Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID576319	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID522003	Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID576066	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529459	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID573601	Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523896	Antibacterial activity against Pseudomonas aeruginosa P341 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558810	Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID499066	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533408	Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523768	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E420	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522016	Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523557	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530814	Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID279814	Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID509026	Volume of distribution at steady state in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID529480	Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID588129	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID548036	Antimicrobial activity against Escherichia coli DH10B by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID433358	Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433363	Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID574687	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID524109	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A928	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523599	Antibacterial activity against Pseudomonas aeruginosa P328 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523760	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433191	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495792	Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID523911	Antibacterial activity against Acinetobacter baumannii A884 incubated up to 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528791	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID576530	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008022 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID495813	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID521282	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype F by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	282 (34.39)	29.6817
2010's	443 (54.02)	24.3611
2020's	95 (11.59)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	89 (10.47%)	5.53%
Reviews	64 (7.53%)	6.00%
Case Studies	101 (11.88%)	4.05%
Observational	12 (1.41%)	0.25%
Other	584 (68.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (70)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Prospective Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections. [NCT01173068]		60 participants (Anticipated)	Observational	2010-08-31	Recruiting
Pharmacodynamics of Ertapenem in Patients With Urosepsis [NCT03859362]	Phase 4	12 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
[NCT02729116]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections [NCT01297842]	Phase 4	100 participants (Anticipated)	Interventional	2011-05-31	Recruiting
A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection [NCT01069900]	Phase 3	458 participants (Actual)	Interventional	2010-07-21	Completed
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complic [NCT03788967]	Phase 3	1,372 participants (Actual)	Interventional	2019-06-03	Completed
Pharmacokinetics and Safety of Ertapenem in the Postpartum Period [NCT01587495]	Phase 1	3 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to study terminated due to low subject accrual)
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections [NCT01844856]	Phase 3	541 participants (Actual)	Interventional	2013-08-31	Completed
A Pilot Study for a Randomized Trial of Antibiotics Versus Surgery for Treatment of Patients With Acute Uncomplicated Appendicitis [NCT02447224]	Early Phase 1	30 participants (Anticipated)	Interventional	2015-03-31	Completed
A Prospective, Multicenter, Partially-Blinded, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of INVANZ Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults [NCT01014013]	Phase 3	271 participants (Actual)	Interventional	2008-04-30	Completed
Pharmacokinetics of Ertapenem Following Subcutaneous or Intravenous Infusion in Patients Aged Over 75 (PHACINERTA) [NCT02505386]	Phase 4	27 participants (Actual)	Interventional	2014-08-31	Completed
Antibiotic Therapy vs. Placebo in the Treatment of Acute Uncomplicated Appendicitis: a Randomized Double-blinded Placebo-controlled Trial - APPAC III Study [NCT03234296]		147 participants (Anticipated)	Interventional	2017-08-09	Enrolling by invitation
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults [NCT01370616]	Phase 3	565 participants (Actual)	Interventional	2011-09-02	Completed
Open-label, Two-period, One Sequence, Multiple Dose, Crossover Study, A Study to Investigate Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Healthy Male Subjects [NCT01073059]	Phase 1	10 participants (Actual)	Interventional	2009-08-31	Completed
A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus it's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults [NCT00157898]	Phase 4	134 participants (Actual)	Interventional	2004-01-31	Completed
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial [NCT02800785]		1,552 participants (Actual)	Interventional	2016-05-31	Completed
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]	Phase 2/Phase 3	170 participants (Actual)	Interventional	2020-01-01	Completed
Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia: a Propensity Score Analysis [NCT03925402]		427 participants (Actual)	Observational	2019-05-15	Completed
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) [NCT03891433]	Phase 4	198 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams [NCT01159379]	Phase 4	30 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety, and PK of 2 Dose Regimens of TP-434 Compared With Ertapenem in Adult Community-Acquired Complicated Intra-abdominal Infections [NCT01265784]	Phase 2	143 participants (Actual)	Interventional	2011-01-31	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
Home Intravenous Versus Oral Antibiotics Following Appendectomy for Perforated Appendicitis in Children, a Randomized Controlled Trial [NCT02724410]		82 participants (Actual)	Interventional	2011-01-31	Completed
Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis: a Prospective Randomised Multicenter Study (The APPAC II Study) [NCT03236961]		552 participants (Anticipated)	Interventional	2017-04-03	Active, not recruiting
A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Comp [NCT00492726]	Phase 3	804 participants (Actual)	Interventional	2006-07-31	Completed
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes [NCT00366249]	Phase 3	1,061 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections [NCT03032510]	Phase 3	1,205 participants (Actual)	Interventional	2017-01-31	Completed
A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli [NCT02537847]	Phase 2	96 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI) [NCT05224401]	Phase 3	330 participants (Anticipated)	Interventional	2023-05-29	Recruiting
A Prospective, Double-blind, Multi Center, Randomized Clinical Study to Compare the Efficacy and Safety of Ertapenem 3 Days Versus Ampicillin-Sulbactam 3 Days in the Treatment of Localized Community Acquired Intra-abdominal Infection (IAI). (T.E.A. Study [NCT00630513]	Phase 4	142 participants (Actual)	Interventional	2008-01-31	Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) In Healthy Adult Subjects [NCT05645757]	Phase 1	54 participants (Actual)	Interventional	2023-04-19	Completed
Comparative Pharmacokinetics, Safety, and Pharmacodynamics of Ertapenem 1 Gram Daily Administered as an IV Bolus Versus Standard 30 Minute Infusion to Healthy Adult Volunteers [NCT01148771]	Phase 4	12 participants (Actual)	Interventional	2010-08-31	Completed
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT) [NCT04886284]	Phase 2	60 participants (Anticipated)	Interventional	2022-07-31	Not yet recruiting
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]	Phase 3	344 participants (Actual)	Interventional	2016-10-31	Completed
Multicenter Prospective Randomized Clinical Trial Comparing Endoscopic Retrograde Appendicitis Therapy (ERAT) vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis [NCT02789865]	Phase 2	240 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia [NCT01886053]	Phase 2	189 participants (Actual)	Interventional	2011-04-30	Completed
A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia [NCT01937832]	Phase 3	540 participants (Anticipated)	Interventional	2013-10-31	Not yet recruiting
Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy [NCT04502095]	Phase 4	100 participants (Anticipated)	Interventional	2020-09-02	Recruiting
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Col [NCT01254344]	Phase 3	599 participants (Actual)	Interventional	2010-12-31	Completed
Antibiotics vs.Surgery in Acute Appendicitis;an Intention to Treat Prospective Randomised Study. The ASAA-study [NCT01421901]	Phase 4	218 participants (Anticipated)	Interventional	2011-08-31	Recruiting
A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdomi [NCT00092170]	Phase 2	100 participants	Interventional	2002-03-31	Completed
A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection [NCT00771316]	Phase 3	6 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to feasibility and low enrollment)
A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue I [NCT00451386]	Phase 2	400 participants	Interventional	2002-01-31	Completed
[NCT00489138]	Phase 4	9 participants (Actual)	Interventional	2007-04-30	Terminated
Study of Surgical Treatment (Open Appendicectomy) Versus Antibiotic Treatment (Ertapenem) in the Treatment of Acute Uncomplicated Appendicitis [NCT01022567]		530 participants (Actual)	Interventional	2009-11-30	Active, not recruiting
Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients [NCT02159859]	Phase 2	7 participants (Actual)	Interventional	2014-12-31	Completed
A Prospective, Multicenter, Open-Label, Randomized Clinical Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis [NCT00097734]	Phase 4	540 participants	Interventional	2004-07-31	Recruiting
Ertapenem Administered Subcutaneously Versus Intravenously for Urinary Tract Infections in Oncological Palliative Care Patients: a Randomized, Open, Non-inferiority Clinical Trial [NCT03218800]	Phase 3	30 participants (Actual)	Interventional	2017-06-01	Terminated(stopped due to not enough participants due to COVID19 pandemia)
A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Col [NCT00090272]	Phase 3	952 participants (Actual)	Interventional	2002-04-30	Completed
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration [NCT02041767]	Phase 4	20 participants (Anticipated)	Interventional	2013-12-31	Completed
Penetration of Ertapenem Into Bone in Patients With Diabetes Mellitus or Peripheral Vascular Diseases Who Underwent Bellow Knee Amputation [NCT00392028]		12 participants (Anticipated)	Interventional	2006-11-30	Withdrawn(stopped due to no recruitment)
An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults [NCT00397956]	Phase 3	30 participants	Interventional	2004-09-30	Completed
Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy [NCT00398099]	Phase 3	30 participants	Interventional	2005-07-31	Completed
Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding [NCT04140578]	Phase 4	150 participants (Anticipated)	Interventional	2017-01-28	Recruiting
SP1 - Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days [NCT01203046]	Phase 2/Phase 3	56 participants (Actual)	Interventional	2010-12-31	Completed
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults. [NCT00229112]	Phase 3	400 participants	Interventional	2001-04-30	Completed
Phase 2 Trial to Evaluate the Early EBA, Safety and Tolerability of Amoxicillin/Clavulanate With or Without Meropenem, Ertapenem or Rifampicin in Adults With Newly Diagnosed, Smear-Positive Rifampicin-Susceptible Pulmonary Tuberculosis [NCT05896930]	Phase 2	134 participants (Actual)	Interventional	2017-11-09	Completed
Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study. [NCT01497990]	Phase 4	8 participants (Actual)	Interventional	2010-01-31	Completed
Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis [NCT01730664]	Phase 2	12 participants (Actual)	Interventional	2017-01-26	Completed
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis [NCT00939952]	Phase 4	7 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 2, Randomized, Double-blind, Positive-control, Multicenter, Prospective Study to Assess Efficacy and Safety of Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) [NCT04505683]	Phase 2/Phase 3	112 participants (Actual)	Interventional	2018-12-13	Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults [NCT03358576]	Phase 3	674 participants (Actual)	Interventional	2018-09-18	Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults [NCT03357614]	Phase 3	1,395 participants (Actual)	Interventional	2018-09-18	Completed
A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections [NCT00379951]	Phase 3	107 participants (Actual)	Interventional	2005-06-30	Completed
New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial [NCT03294395]	Phase 3	346 participants (Actual)	Interventional	2017-09-18	Completed
Acute Appendicitis and Microbiota - Ethology of Appendicitis and Effects of the Antimicrobial Treatment - The MAPPAC (Microbiology Appendicitis Acuta) Trial [NCT03257423]		200 participants (Anticipated)	Interventional	2017-04-04	Enrolling by invitation
A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa [NCT05255575]		0 participants (Actual)	Observational	2018-03-01	Withdrawn(stopped due to unavailable staff to support project)
A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess [NCT01723150]	Phase 4	152 participants (Actual)	Interventional	2013-11-05	Completed
Konzentrationen Von Ertapenem in Kolorektalem Gewebe [NCT00535652]	Phase 4	23 participants (Actual)	Interventional	2007-09-30	Completed
Pharmacokinetics of Invanz® (Ertapenem) in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis [NCT00877370]	Phase 4	8 participants (Actual)	Interventional	2009-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure.
NCT00366249 (5) [back to overview]	Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.
NCT00366249 (5) [back to overview]	Number of Patients With Microbiologic Response of Eradication.
NCT00492726 (10) [back to overview]	Number of Subjects Who Died Due to Intra-abdominal Infections
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Duration of Hospitalization Postoperatively
NCT00492726 (10) [back to overview]	Duration of Hospitalization
NCT00535652 (1) [back to overview]	Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue
NCT00877370 (1) [back to overview]	Ertapenem Transmembrane Clearance by Continuous Hemodialysis.
NCT00939952 (7) [back to overview]	k12
NCT00939952 (7) [back to overview]	Clearance (CL)
NCT00939952 (7) [back to overview]	Volume of Distribution, Central Compartment (Vc)
NCT00939952 (7) [back to overview]	Residual Drug in Peritoneal Cavity After 1st Exchange
NCT00939952 (7) [back to overview]	k31
NCT00939952 (7) [back to overview]	k21
NCT00939952 (7) [back to overview]	k13
NCT01014013 (3) [back to overview]	Clinical Response Assessment Profile
NCT01014013 (3) [back to overview]	Microbiological Response Assessment Profile
NCT01014013 (3) [back to overview]	The Number of Patients Who Experience Any Drug-related Adverse Experiences Leading to Discontinuation of Parenteral Study Drug and the Number of Patients With Any Drug-related Serious Adverse Experiences (AEs) During Parenteral Treatment
NCT01022567 (1) [back to overview]	The Success of Antibiotic and Surgical Treatment in the Treatment of Acute Uncomplicated Appendicitis
NCT01069900 (20) [back to overview]	Bacteriological Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	Bacteriological Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Bacteriological Response at the End of Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	Clinical Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)
NCT01069900 (20) [back to overview]	Clinical Response at the End-of-Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term
NCT01069900 (20) [back to overview]	Number of Subjects With Adverse Events
NCT01069900 (20) [back to overview]	Number of Subjects With Clinical Cardiac Adverse Events
NCT01069900 (20) [back to overview]	Number of Subjects With Musculoskeletal Adverse Events
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01148771 (4) [back to overview]	Probability of Target Attainment (PTA)
NCT01148771 (4) [back to overview]	Number of Participants With Adverse Events as a Measure of Safety and Tolerability
NCT01148771 (4) [back to overview]	Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose)
NCT01148771 (4) [back to overview]	Area Under the Curve From 48 to 72 Hours [AUC(48-72)]
NCT01203046 (2) [back to overview]	Other Complications
NCT01203046 (2) [back to overview]	Surgical Site Infection
NCT01254344 (2) [back to overview]	Percentage of Participants With Success of Prophylaxis
NCT01254344 (2) [back to overview]	Percentage of Participants With Favorable Clinical Response
NCT01265784 (21) [back to overview]	Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the EOT Visit
NCT01265784 (21) [back to overview]	Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the TOC Visit
NCT01265784 (21) [back to overview]	Microbiologic Response to TP-434 and Ertapenem in the ME Population at the EOT Visit
NCT01265784 (21) [back to overview]	Microbiologic Response to TP-434 and Ertapenem in the ME Population at the TOC Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the End-of-Treatment (EOT) Visit
NCT01265784 (21) [back to overview]	Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434
NCT01265784 (21) [back to overview]	Pharmacokinetics: Maximum Concentration (Cmax) of TP-434
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the EOT Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the Follow-up Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the TOC Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the EOT Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the Follow-up Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the TOC Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the EOT Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Follow-up Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the EOT Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the Follow-up Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the TOC Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the Follow-up Visit
NCT01265784 (21) [back to overview]	Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at TOC Visit
NCT01370616 (9) [back to overview]	Percentage of Participants With Drug-related AEs
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV)
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Day 5 of IV Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Serious AEs (SAEs)
NCT01370616 (9) [back to overview]	Percentage of Participants With One or More Adverse Events (AEs)
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants With Favorable Clinical Response Assessments at Follow-up Assessment (FUA) Day 10 of Post-antibiotic Study Therapy
NCT01370616 (9) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to an AE
NCT01370616 (9) [back to overview]	Percentage of Participants With Both Favorable Clinical and Microbiological Response Assessments at FUA Day 10 of Post-antibiotic Study Therapy
NCT01844856 (3) [back to overview]	Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population
NCT01844856 (3) [back to overview]	Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Clinically Evaluable (CE) Population at the TOC Visit
NCT01844856 (3) [back to overview]	Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Modified Intent-to-treat (MITT) Population at the TOC Visit
NCT02159859 (10) [back to overview]	Number of Participants With Any Adverse Events
NCT02159859 (10) [back to overview]	Number of Participants With Nausea and Vomiting
NCT02159859 (10) [back to overview]	Number of Participants With Injection Site Reaction
NCT02159859 (10) [back to overview]	Number of Participants With Headache
NCT02159859 (10) [back to overview]	Number of Participants With Diarrhea
NCT02159859 (10) [back to overview]	Mean Time to Cmax of Ertapenem in Hemodialysis Patients
NCT02159859 (10) [back to overview]	Mean Terminal Half Life (t1/2) of Ertpenem in Hemodialysis Patients
NCT02159859 (10) [back to overview]	Mean Minimum Concentration (Cmin) of Ertapenem in Hemodialysis Patients
NCT02159859 (10) [back to overview]	Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients
NCT02159859 (10) [back to overview]	Mean Area Under the Curve (AUC) of Ertapenem in Hemodialysis Patients
NCT02724410 (4) [back to overview]	Number of Participants With Postoperative Abscess
NCT02724410 (4) [back to overview]	Number of Participants With Wound Infections
NCT02724410 (4) [back to overview]	Number Participants With Readmission Within 30 Days
NCT02724410 (4) [back to overview]	Hospital Charge
NCT02800785 (8) [back to overview]	Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)
NCT02800785 (8) [back to overview]	Number of Participants With at Least One Complications From Treatment
NCT02800785 (8) [back to overview]	Eventual Appendectomy Incidence Proportion
NCT02800785 (8) [back to overview]	Days in Hospital After Index Treatment Within 90 Days
NCT02800785 (8) [back to overview]	Number of Clinic Visits or Emergency Room Visits
NCT02800785 (8) [back to overview]	Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days
NCT02800785 (8) [back to overview]	Rates of Participants With Appendiceal Cancer
NCT02800785 (8) [back to overview]	Rate of Participants With Perforated Appendicitis
NCT03357614 (2) [back to overview]	Percentage of Participants With Microbiologic Success
NCT03357614 (2) [back to overview]	Percentage of Participants With Overall Success
NCT03358576 (2) [back to overview]	Percentage of Participants With Clinical Success
NCT03358576 (2) [back to overview]	Percentage of Participants With Clinical Success
NCT03788967 (38) [back to overview]	Clinical Cure at EOT in the ME-EOT Populations
NCT03788967 (38) [back to overview]	Clinical Cure at TOC Days in the ME-TOC Populations
NCT03788967 (38) [back to overview]	Clinical Cure at TOC in the CE-TOC Populations
NCT03788967 (38) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population
NCT03788967 (38) [back to overview]	Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population
NCT03788967 (38) [back to overview]	Rate of Clinical Relapse at the LFU Days in the Micro-ITT Population
NCT03788967 (38) [back to overview]	Systemic Clearance (CL) in TBPM-PI-HBr Recipients in the PK Population
NCT03788967 (38) [back to overview]	By-Pathogen Sustained Microbiological Eradication Rate at LFU in the Micro-ITT Population (m-ITT)
NCT03788967 (38) [back to overview]	By-Pathogen Sustained Microbiological Eradication Rate at LFU in the Micro-ITT Population (m-ITT)
NCT03788967 (38) [back to overview]	By-pathogen Microbiological Eradication Rate in Participants at TOC in the ME-TOC Populations
NCT03788967 (38) [back to overview]	By-pathogen Microbiological Eradication Rate in Participants at TOC in the ME-TOC Populations
NCT03788967 (38) [back to overview]	By-pathogen Sustained Microbiological Eradication Rate in Participants at LFU in the ME-LFU Populations
NCT03788967 (38) [back to overview]	By-pathogen Microbiological Eradication Rate in Participants at EOT in the ME-EOT Populations
NCT03788967 (38) [back to overview]	By-Pathogen Microbiological Eradication Rate at TOC in the Micro-ITT Population
NCT03788967 (38) [back to overview]	By-Pathogen Microbiological Eradication Rate at TOC in the Micro-ITT Population
NCT03788967 (38) [back to overview]	By-Pathogen Microbiological Eradication Rate at EOT in the Micro-ITT Population
NCT03788967 (38) [back to overview]	By-Pathogen Microbiological Eradication Rate at EOT in the Micro-ITT Population
NCT03788967 (38) [back to overview]	Area Under Curve (AUC 0-24) in TBPM-PI-HBr Recipients in the PK Population
NCT03788967 (38) [back to overview]	By-pathogen Microbiological Eradication Rate in Participants at EOT in the ME-EOT Populations
NCT03788967 (38) [back to overview]	Apparent Volume of Distribution (Vss) at Steady State in TBPM-PI-HBr Recipients in the Pharmacokinetic (PK) Population
NCT03788967 (38) [back to overview]	Time (Days) to Resolution or Improvement of Signs and Symptoms of cUTI and AP Present a Baseline in the Micro-ITT Populations
NCT03788967 (38) [back to overview]	Sustained Clinical Cure at LFU in the ME-LFU Population
NCT03788967 (38) [back to overview]	Sustained Clinical Cure at LFU in the CE-LFU Populations
NCT03788967 (38) [back to overview]	By-pathogen Sustained Microbiological Eradication Rate in Participants at LFU in the ME-LFU Populations
NCT03788967 (38) [back to overview]	Time (Days) to Defervescence in Micro-ITT Population With a Documented Fever at Screening or Day 1
NCT03788967 (38) [back to overview]	Rates Of Superinfection And New Infection In The Micro-ITT Population
NCT03788967 (38) [back to overview]	Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) In Subgroup Including: Stratified Infection Category
NCT03788967 (38) [back to overview]	By-Patient Microbiological Eradication at EOT in the ME-EOT Populations
NCT03788967 (38) [back to overview]	Overall Response (Combined Clinical Cure Plus Microbiological Eradication) At Test-Of-Cure (TOC) In The Microbiologically Evaluable (ME) - TOC Population
NCT03788967 (38) [back to overview]	Minimum Concentration (Cmin) in TBPM-PI-HBr Recipients in the PK Population
NCT03788967 (38) [back to overview]	Cmax in TBPM-PI-HBr Recipients in the PK Population
NCT03788967 (38) [back to overview]	Clinical Cure at End-of-Treatment (EOT), TOC, and Sustained Clinical Cure at Late Follow-Up (LFU) Days in the Micro-ITT Populations
NCT03788967 (38) [back to overview]	Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Stratified Age Category
NCT03788967 (38) [back to overview]	By-Patient Microbiological Eradication at TOC in the ME-TOC Population
NCT03788967 (38) [back to overview]	By-Patient Sustained Microbiological Eradication at LFU Days in the ME-LFU Populations
NCT03788967 (38) [back to overview]	Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations
NCT03788967 (38) [back to overview]	By-Patient Microbiological Eradication at EOT, TOC, and Sustained Microbiological Eradication at LFU Days in the Micro-ITT Population
NCT03788967 (38) [back to overview]	Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Including Region

Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.

Cure: Recovery so no added antibiotic therapy. Failure: Added antibiotic therapy for no response or worsening after improvement, new purulence, >120% doses, non-routine surgical treatment or death related to DFI > 48 hrs. Indeterminate: Lost to follow-up, death<48 hours or noninfection related. (NCT00366249)
Timeframe: Test of cure visit (TOC): Assessed at least 12 days post last dose

Intervention	patients (Number)
	Cure	Failure	Indeterminate
Ertapenem	363	86	17
Tigecycline	340	117	19

Intervention	participants (Number)
	Clinical Improvement	Clinical Failure	Missing
Ertapenem	194	2	151
Moxifloxacin (Avelox, BAY12-8039)	210	0	142

Intervention	participants (Number)
	Clinical Cure	Clinical Failure
Ertapenem	254	22
Moxifloxacin (Avelox, BAY12-8039)	265	32

Intervention	participants (Number)
	Eradication	Presumed Eradication	Persistence	Presumed Persistence	Superinfections
Ertapenem	5	149	7	2	1
Moxifloxacin (Avelox, BAY12-8039)	5	170	16	0	0

Intervention	Participants (Number)
	Discontinued due to drug-related clinical AEs	Serious drug-related clinical AEs	Discontinued due to drug-related laboratory AEs	Serious drug-related Laboratory AEs
Ceftriaxone	0	0	1	0
MK0826	1	0	1	0

Intervention	Percentage of subjects (Number)
	Resolution	Clinical Failure	Indeterminate
Comparator Ertapenem	98	0.7	1.4
Moxifloxacin (Avelox, BAY12-8039)	92.2	4.6	3.2

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 298, 150)	Change at Day 1 (N= 290, 148)	Day 3: Pre-dose (N= 292, 146)	Change at Day 3 (N= 287, 146)
Comparator Ertapenem	417.34	2.2905	412.7945	1
Moxifloxacin (Avelox, BAY12-8039)	419.5872	9.731	419.2055	9.2509

Intervention	Beats per minute (bpm) (Mean)
	Day 1: Pre-dose (N= 300, 150)	Change at Day 1 ((N= 294, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 290, 146)
Comparator Ertapenem	90.4	0.3	82.6	-0.9
Moxifloxacin (Avelox, BAY12-8039)	93.4	2.8	84.3	1

Intervention	Percentage of subjects (Number)
	Forearm fracture	Joint injury	Ligament sprain	Muscle strain	Arthralgia	Joint swelling	Musculoskeletal pain	Myalgia
Comparator Ertapenem	0	0.7	0.7	0.7	1.3	0.7	0	0
Moxifloxacin (Avelox, BAY12-8039)	0.3	0	0.3	0	3	0	1	0.3

Intervention	Subjects (Number)
	Any AE	Any SAE
Comparator Ertapenem	82	6
Moxifloxacin (Avelox, BAY12-8039)	175	20

Intervention	Percentage of subjects (Number)
	Day1: Pre-dose QTc Calc Bazett > ULN (N= 300, 150)	Day1: Post-dose QTc Calc Bazett > ULN (N= 297,148)	Day1: Post-dose >30 ms from pre-dose (N= 297,148)	Day1: Post-dose >60 ms from pre-dose (N= 297,148)	Day3: Pre-dose QTc Calc Bazett > ULN (N= 293, 146)	Day3: Post-dose QTc Calc Bazett > ULN (N= 291,148)	Day3: Post-dose >30 ms from pre-dose (N= 291,148)	Day3: Post-dose >60 ms from pre-dose (N= 291,148)
Comparator Ertapenem	2.7	4.1	0	0	1.4	3.4	2	0.7
Moxifloxacin (Avelox, BAY12-8039)	7.7	16.2	5.4	0	3.8	15.5	9.6	0.7

Intervention	Percentage of subjects (Number)
	Day1: Pre-dose QTcCalcFridericia>ULN (N= 300, 150)	Day1: Post-dose QTcCalcFridericia>ULN (N= 297,148)	Day1: Post-dose >30 ms from pre-dose (N= 297,148)	Day1: Post-dose >60 ms from pre-dose (N= 297,148)	Day3: Pre-dose QTcCalcFridericia>ULN (N= 293, 146)	Day3: Post-dose QTcCalcFridericia>ULN (N= 291,148)	Day3: Post-dose >30 ms from pre-dose (N= 291,148)	Day3: Post-dose >60 ms from pre-dose (N= 291,148)
Comparator Ertapenem	1.3	2	0	0	1.4	1.4	3.4	0.7
Moxifloxacin (Avelox, BAY12-8039)	0.7	3	2	0.3	1.4	9.6	17.9	1.7

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 299, 150)	Change at Day 1 ( N= 292, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 289, 146)
Comparator Ertapenem	140.5933	-0.0203	139.5685	1.5616
Moxifloxacin (Avelox, BAY12-8039)	136.8294	0.7123	139.4915	1.5813

Intervention	milliseconds (Mean)
	Day 1: Pre-dose (N= 300, 150)	Change at Day 1 (N= 294, 148)	Day 3: Pre-dose (N= 293, 146)	Change at Day 3 (N= 289, 146)
Comparator Ertapenem	88.8067	1.223	89.3904	0.2877
Moxifloxacin (Avelox, BAY12-8039)	89.0333	0.119	89.2423	0.2768

Intervention	% of 5000 simulated patients (Number)
	PTA at 0.25	PTA at 0.5
Ertapenem 1 Gram IV 30 Minute Infusion	97.9	2.8
Ertapenem 1 Gram IV 5 Minute Bolus	97.0	1.7

Intervention	participants (Number)
Ertapenem IV 5 Minute Bolus	10
Ertapenem IV 30 Minute Infusion	9

Intervention	mcg/mL (Mean)
Ertapenem 1 Gram IV 5 Minute Bolus	193.33
Ertapenem 1 Gram IV 30 Minute Infusion	165.70

Intervention	mcg*hr/mL (Mean)
Ertapenem 1 Gram IV 5 Minute Bolus	561.17
Ertapenem 1 Gram IV 30 Minute Infusion	531.32

Intervention	participants (Number)
	Favorable	Unfavorable	Indeterminate
Ertapenem 1 g q24h	26	1	0
TP-434, 1.0 mg/kg q12h	44	0	3
TP-434, 1.5 mg/kg q24h	41	2	2

Intervention	nanogramhours per milliliter (ngh/mL) (Mean)
TP-434, 1.5 mg/kg q24h	4349.900
TP-434, 1.0 mg/kg q12h	3240.724

Intervention	Participants (Count of Participants)
Home Intravenous Ertapenem and PICC	5
Home Oral Amoxicillin-clavulanate	3

ertapenem

Description

Cross-References

Synonyms (52)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (2)

Protein Targets (4)

Other Measurements

Bioassays (1515)

Research

Studies (820)

Market Indicators

Research Demand Index: 92.81

Study Types

Clinical Trials (70)

Trial Overview

Trial Outcomes

Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.

Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.

Number of Patients With Clinical Response of Cure Vs. Failure.

Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.

Number of Patients With Microbiologic Response of Eradication.

Number of Subjects Who Died Due to Intra-abdominal Infections

Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population

Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)

Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population

Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population

Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)

Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)

Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)

Duration of Hospitalization Postoperatively

Duration of Hospitalization

Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue

Ertapenem Transmembrane Clearance by Continuous Hemodialysis.

k12

Clearance (CL)

Volume of Distribution, Central Compartment (Vc)

Residual Drug in Peritoneal Cavity After 1st Exchange

k31

k21

k13

Clinical Response Assessment Profile

Microbiological Response Assessment Profile

The Number of Patients Who Experience Any Drug-related Adverse Experiences Leading to Discontinuation of Parenteral Study Drug and the Number of Patients With Any Drug-related Serious Adverse Experiences (AEs) During Parenteral Treatment

The Success of Antibiotic and Surgical Treatment in the Treatment of Acute Uncomplicated Appendicitis

Bacteriological Response at a 'During Therapy' Visit

Bacteriological Response at Test-of-Cure (TOC) Visit

Bacteriological Response at the End of Treatment (EOT) Visit

Clinical Response at a 'During Therapy' Visit

Clinical Response at Test-of-Cure (TOC) Visit

Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)

Clinical Response at the End-of-Treatment (EOT) Visit

Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term

Number of Subjects With Adverse Events

Number of Subjects With Clinical Cardiac Adverse Events

Number of Subjects With Musculoskeletal Adverse Events

Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3

Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3

PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3

QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

Probability of Target Attainment (PTA)

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose)

Area Under the Curve From 48 to 72 Hours [AUC(48-72)]

Other Complications

Surgical Site Infection

Intervention	Dollars (Mean)
Home Intravenous Ertapenem and PICC	47564.3
Home Oral Amoxicillin-clavulanate	34227.79

Intervention	percentage of pathogen eradication (Number)
	Citrobacter braakii	Citrobacter freundii	Citrobacter koseri	Enterobacter amnigenus	Enterobacter asburiae	Enterobacter bugandensis	Enterobacter cloacae	Enterococcus faecalis	Enterococcus faecium	Escherichia coli	Klebsiella aerogenes	Klebsiella oxytoca	Klebsiella pneumoniae	Klebsiella variicola	Morganella morganii	Proteus mirabilis	Proteus penneri	Proteus vulgaris	Providencia rettgeri	Providencia stuartii	Serratia liquefaciens	Serratia marcescens	Staphylococcus aureus	Staphylococcus lugdunensis	Staphylococcus saprophyticus
Ertapenem 1 g	100	100	50.0	100	0	100	37.5	50.0	100	60.0	0.0	33.3	60.6	75.0	100	60.9	100	100	100	100	100	100	37.5	100	83.3

Intervention	percentage of pathogen eradication (Number)
	Enterobacterales, Citrobacter braakii	Enterobacterales, Citrobacter freundii	Enterobacterales, Citrobacter koseri	Enterobacterales, Enterobacter amnigenus	Enterobacterales, Enterobacter asburiae	Enterobacterales, Enterobacter bugandensis	Enterobacterales, Enterobacter cloacae	Enterobacterales, Escherichia coli	Enterobacterales, Klebsiella oxytoca	Enterobacterales, Klebsiella pneumoniae	Enterobacterales, Klebsiella variicola	Enterobacterales, Morganella morganii	Enterobacterales, Proteus mirabilis	Enterobacterales, Proteus penneri	Enterobacterales, Proteus vulgaris	Enterobacterales, Providencia rettgeri	Enterobacterales, Providencia stuartii	Enterobacterales, Serratia liquefaciens	Enterobacterales, Serratia marcescens	Gram Positive, Enterococcus faecalis	Gram Positive, Enterococcus faecium	Gram Positive, Staphylococcus aureus	Gram Positive, Staphylococcus lugdunensis	Gram Positive,Staphylococcus saprophyticus
Ertapenem	100	100	66.7	100	100	100	50.0	68.3	50.0	71.0	75.0	100	76.2	100	100	100	100	100	100	57.6	100	50.0	100	83.3

Intervention	percentage of participants (Number)
	Superinfection	New Infection
Ertapenem 1 g	2.1	1.9
TBPM-PI-HBr 600 mg	0.2	1.1

Intervention	percentage of participants (Number)
	≥18 to <65 years	≥65 to <75 years	≥75 years
Ertapenem 1 g	65.3	57.6	56.9
TBPM-PI-HBr 600 mg	66.7	49.2	49.4

Intervention	percentage of participants (Number)
	Central and Eastern Europe	South Africa	United States
Ertapenem 1 g	62.0	0.0	50.0
TBPM-PI-HBr 600 mg	58.9	100	0.0